Document:

<PAGE>
                                                                   Exhibit 10.12

               SUPPLY AND DISTRIBUTION AGREEMENT: COMMERCIAL PHASE

THIS AGREEMENT (the "AGREEMENT") is entered into by and between OMRIX
BIOPHARMACEUTICALS, LTD., an Israeli company (hereinafter, "OMRIX"), and FFF
ENTERPRISES, INC., a United States ("US") corporation organized and existing
under the laws of California (hereinafter, "FFF"), together with Omrix, the
"PARTIES" and each individually a "PARTY."

WHEREAS:

A.   Omrix manufactures Omrigam NF, a proprietary immune globulin intravenous
     ("IGIV") for use in patients with primary immune deficiency, and wishes to
     obtain FDA approval of a Biologics License Application ("BLA") to market
     Omrigam NF in the US;

B.   FFF is a wholesale distributor of pharmaceutical products, including IGIV
     products, in North America and wishes to be the exclusive distributor of
     Omrigam NF in the United States of America ("US") subsequent to FDA
     approval of the BLA for Omrigam;

C.   The Parties have agreed to enter into a Supply and Distribution Agreement:
     Investigational Phase (the "INVESTIGATIONAL AGREEMENT"), attached hereto as
     Exhibit A;

D.   Under the Investigational Agreement, FFF will assume sponsorship of the
     Investigational New Drug Application for Omrigam NF and will take
     responsibility for conducting clinical trials and distributing Omrigam NF
     under a treatment protocol;

E.   The term of the Investigational Agreement ends upon FDA approval of the BLA
     to market Omrigam NF in the US; and

F.   Omrix wishes to designate FFF as its exclusive authorized distributor to
     market Omrigam NF in the US, and FFF wishes to accept such designation, all
     under the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the mutual promises and covenants contained
herein, effective upon the Effective Date, the Parties agree as follows:

1.   EFFECTIVE DATE

     This Agreement shall be effective immediately upon execution by the
     Parties, except Sections 3.4, 4, 5, 6, 11 and 12, which shall become
     effective on the date the FDA issues written notice (which will be attached
     hereto as Exhibit B and incorporated as part of this Agreement upon its
     issuance) that it has approved a Biologics License to market Omrigam NF in
     the US for use in humans with primary immune deficiency (hereafter the
     "APPROVAL DATE").

2.   DEFINITIONS

     As used in this Agreement the following definitions shall apply in each
     case where the defined term appears in capitalized form:

     2.1  "AFFILIATE" - means any entity controlled by, controlling, or under
          common control with a Party to this Agreement, through ownership or
          control of more than 50% of the voting power of the shares or other
          means of ownership or control, provided that such control continues to
          exist.

     2.2  "BATCH" - means all material intended to have uniform character and
          quality that is produced from a single manufacturing procedure in
          accordance with established parameters and according to a single
          manufacturing order during that same cycle of manufacture.

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 1 of 29

PORTIONS OF THIS EXHIBIT MARKED BY AN *** HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
<PAGE>

     2.3  "BLA" - means a Biologics License Application, as defined in 21 CFR
          Section 601.2, to market Omrigam NF in the US for use in patients with
          primary immune deficiency.

     2.4  "CALENDAR YEAR" - means the period beginning on January 1 and ending
          on December 31 of each year.

     2.5  "CFR" - means the US Code of Federal Regulations, as may be amended
          from time to time, and any successor thereto.

     2.6  "CGMP" - means current Good Manufacturing Practice and General
          Biological Products Standards as defined in 21 CFR Parts 210, 211, 600
          and 606.

     2.7  "COMMERCIAL PHASE" - means the phase of a relationship between the
          Parties after FDA approval of a BLA of Omrigam NF has been obtained
          and Omrigam NF may be marketed in the US for use in humans with
          primary immune deficiency.

     2.8  "DCI CONTRACT" - means the Plasma Supply Agreement between Omrix and
          DCI Management Group, LLC, attached hereto as Exhibit C, execution of
          which is a condition precedent to this Agreement.

     2.9  "FDA" - means the US Food and Drug Administration.

     2.10 "HANDLING SPECIFICATIONS" - means the specifications for the handling,
          the storage, the use, the transport and the general possession of the
          Product by FFF as agreed upon by the Parties in consideration of the
          specifications and standards defined and specified in an approved BLA
          for the Product, as more fully described in Exhibit D hereto. The
          Handling Specifications may be amended from time to time by the
          Parties as provided under this Agreement.

     2.11 "IGIV" - means immune globulin intravenous.

     2.12 "INVESTIGATIONAL PHASE" - means the phase of relationship between the
          Parties described in the Investigational Agreement, which covers
          exclusive use by FFF and its agents of Omrigam NF in clinical trials
          and exclusive distribution by FFF of Omrigam NF under a treatment
          protocol (as defined in 21 CFR Section 312.34), provided that a
          treatment protocol is approved by the FDA.

     2.13 "MASTER BATCH RECORD" - means the criteria, methodology, manufacturing
          Process, Specifications and formulae for the Product, which includes
          the identity and quantities of the Raw Materials and other components,
          as such may be amended by mutual agreement of the Parties from time to
          time.

     2.14 "OMRIGAM NF" - means Omrix's proprietary polyvalent IGIV, as further
          described in Exhibit E hereto.

     2.15 "OTHER TAXES" - means all taxes, other than US Taxes, associated with
          the marketing, distribution, sale and delivery of the Product,
          including but not limited to all sales and export taxes imposed by the
          Israeli government.

     2.16 "PROCESSING," "PROCESS," and "PROCESSED" - have comparable meanings
          and mean the act of manufacturing and inspecting the Product in
          accordance with the Master Batch Record and specified procedures.

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 2 of 29

<PAGE>

     2.17 "PRODUCT" - means Omrigam NF approved by the FDA for commercial
          distribution for use in humans with primary immune deficiency only by
          means of a Biologics License as defined in 21 CFR Part 601.

     2.18 "QUALIFIED PERSON" - means any person who possesses the skills,
          experience, education, and authority to perform a task or job
          described in this Agreement.

     2.19 "RAW MATERIALS" - means the plasma, excipients and associated
          manufacturing components, all of which are utilized in Processing. The
          plasma used to manufacture the Product or any component thereof shall
          at all times be obtained from US licensed collection centers.

     2.20 "REGULATORY FILINGS" - means any document or report required to be
          filed for an FDA approved biological product under the US Federal
          Food, Drug and Cosmetics Act and associated regulations in Title 21 of
          the CFR, including without limitation any supplement to an approved
          BLA and any postmarketing report for the biological product.

     2.21 "SPECIFICATIONS" - means, with respect to the Product, the
          Specifications for Processing the Product as agreed upon by the
          Parties in consideration of the specifications and standards defined
          and specified in an approved BLA for the Product, as more fully
          described in Exhibit F hereto. The Specifications may be amended from
          time to time by the Parties as provided under this Agreement.

     2.22 "TECHNOLOGY" - means all the technical information, whether tangible
          or intangible, including (without limitation) any and all data,
          techniques, discoveries, inventions, Processes, formulations,
          know-how, patents (including any divisional, continuation, extension,
          reissue, reexamination certificate, or renewal patents), patent
          applications, inventor certificates, trade secrets, method of
          production and other proprietary information, that Omrix has rights to
          (as either owner, licensee or sublicense), or may hereafter obtain
          rights to, relating to the Product.

     2.23 "TERM" - as defined in Section 7.1, below.

     2.24 "US TAXES" - means all taxes associated with the marketing,
          distribution, sale and delivery of the Product that are due, payable
          and/or collectable under the laws of US federal, state, and/or local
          government, including but not limited to sales, use, excise,
          withholding, value-added and similar taxes and all customs, duties or
          other US governmental impositions, but excluding taxes calculated on
          Omrix's income.

3.   GRANT OF RIGHTS

     3.1  FFF Rights. Omrix owns certain Technology and facilities to
          manufacture the Product. Omrix agrees to use the Technology to
          manufacture the Product for FFF subject to the terms and conditions
          set forth in this Agreement. Except as otherwise provided in section
          5.2.d and 5.2.e, FFF shall have and Omrix hereby grants to FFF the
          exclusive right (exclusive even as to Omrix and its Affiliates) to
          distribute, market, offer for sale, sell, import and promote the
          Product in the US.

     3.2  Omrix Obligations. Omrix agrees that:

          a.   Omrix shall use reasonable commercial efforts to reply to
               technical and commercial queries received from FFF in the course
               of the performance of its obligations hereunder and shall provide
               FFF with such technical assistance and technical, professional,
               and clinical data and information as Omrix and

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 3 of 29

<PAGE>
               FFF, working together, determine are reasonably necessary for the
               promotion and solicitation of sale of the Product in the US;

          b.   Omrix and its Affiliates shall not engage in any marketing,
               promotion, advertisement, sale or distribution of the Product
               within the US including placing resale and export restrictions in
               all contracts for the sale of the Product to third parties other
               than FFF; and;

          c.   Omrix shall not use its Technology, or allow any of its
               Affiliates or any third party to use its Technology (e.g., by
               grant of a license), for the purpose of competing with FFF,
               directly or indirectly, in the US.

     3.3  Omrix Rights. Except as provided in Section 3.2 above, Omrix shall
          retain all rights to develop, distribute, market, offer for sale,
          sell, import and promote the Product outside the US.

     3.4  FFF Obligations. FFF agrees that:

          a.   FFF shall use commercially reasonable efforts to sell, market,
               and distribute the Product in the US, faithfully and diligently
               perform its obligations as Omrix's distributor, and
               professionally promote and develop the sale and use of the
               Product in the US;

          b.   FFF shall perform all marketing and sales activities for the
               Product in the US, including, but not limited to, promotion of
               the Product by way of meetings, seminars, advertisement in
               magazines, participation in exhibitions, sales of the Product and
               after sales support;

          c.   FFF shall make written periodic reports, at least quarterly,
               commencing in the quarter in which the BLA is approved by the
               FDA, specifying: (i) the promotional activities carried out by
               FFF in the reported quarter; and (ii) complaints and requests of
               customers of which FFF is aware. FFF shall promptly report to
               Omrix any significant developments that could be reasonably
               foreseen to have an immediate material adverse impact on its
               marketing activities in the US;

          d.   FFF shall conduct business in a manner that reflects favorably at
               all times on the Product, goodwill and reputation of Omrix and
               avoid deceptive, misleading or unethical practices, and refrain
               from making any representations, warranties or guarantees with
               respect to the Product that are known by FFF to be inconsistent
               with those made by Omrix in its published or provided literature
               for the Product. FFF shall submit to Omrix for its prompt review
               and approval all promotional material intended by FFF for use in
               the promotion of the Product;

          e.   FFF shall appoint a Qualified Person as a product manager to
               serve as a liaison and chief point of contact between FFF and
               Omrix for all marketing, sales, and technical issues related to
               the Product;

          f.   FFF shall employ a professional sales and technical support
               organization to provide sales and technical support for Product
               to its customers;

          g.   FFF shall keep Omrix informed as to problems encountered and
               resolutions proposed in relation to the Product and communicate
               promptly to Omrix all modifications, design changes, or
               improvement of the Product suggested by

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 4 of 29

<PAGE>
               any customers, or any employee of FFF, provided that Omrix
               shall be and remain the exclusive owner of such information in
               connection with the Product;

          h.   FFF shall refrain from incurring any liability on behalf of Omrix
               except as expressly authorized by this Agreement; and

          i.   FFF shall not sell, market, offer for sale, sell, import and
               promote the Product outside the US.

4.   REGULATORY MATTERS

     4.1  General. In connection with performing their obligations pursuant to
          this Agreement, FFF and Omrix shall use all commercially reasonable
          efforts to perform such responsibilities diligently, with the
          objective of maximizing the sales potential of the Product and
          promoting the therapeutic profile and benefits of the Product in the
          most commercially beneficial manner. Without limiting the generality
          of the foregoing, each Party shall, at its own expense, except as
          otherwise specifically provided in this Agreement:

          a.   Collaborate and cooperate in the preparation and filing of all
               Regulatory Filings as defined in Section 2.20, above and all
               other aspects necessary to implement this Agreement;

          b.   Use commercially reasonable efforts to perform the work set out
               for such Party to perform in this Agreement;

          c.   Conduct all work pursuant to this Agreement in compliance in all
               material aspects with all requirements of applicable laws, rules
               and regulations, and all other requirements of any applicable
               cGMP to achieve the objectives of this Agreement efficiently and
               expeditiously; and

          d.   Maintain records in sufficient detail, which shall be complete
               and accurate and shall fully and properly reflect all work done
               and results achieved in connection with the Product in the form
               required under all applicable laws and regulations.

     4.2  Ownership. Omrix shall own the Biologics License for the Product, and
          any reissuance or reinstatement thereof. Omrix shall also own all
          Regulatory Filings in connection with the Product.

     4.3  Duties.

          a.   As the owner of the Biologics License for the Product, Omrix
               shall be primarily responsible for preparing and filing all
               Regulatory Filings, including any supplemental applications and
               postmarketing reports as required by 21 CFR Parts 314, 600 and
               601. Omrix shall consult with FFF in preparing all Regulatory
               Filings and FFF shall provide Omrix with timely assistance and
               information necessary to prepare Regulatory Fillings as required.

          b.   Omrix shall be responsible for conducting all communications with
               the FDA regarding the Product. Omrix shall provide FFF with
               copies of all correspondence received from the FDA regarding the
               Product, including any FDA adverse product experience reports as
               defined in 21 CFR Section 600.80 or MEDWATCH reports forwarded to
               Omrix by the FDA. Additionally, Omrix shall discuss with FFF any
               commitments to the FDA prior to agreeing to them.

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 5 of 29

<PAGE>

          c.   Omrix shall be responsible for compliance of the manufacturing
               and Processing procedures in accordance with the Specifications.

     4.4  Notices Regarding Product. Omrix and FFF shall each give the other
          prompt notice of any information either of them receives regarding the
          safety of the Raw Materials or the Product, including any confirmed or
          unconfirmed information on adverse experience or unexpected adverse
          experience, as defined in 21 CFR Part 600, associated with the use of
          the Product. For serious adverse experience or unexpected adverse
          experience, as defined in 21 CFR Part 600, notice must be given by
          telephone within one (1) business day after receipt of the information
          and followed by written notice not less than one (1) week thereafter.
          Omrix shall be responsible for all responses due and cost for filing
          any report with the FDA concerning such adverse reactions associated
          with the use of the Product, as required by applicable laws and
          regulations (including 21 CFR Section 600.80).

5.   PRODUCT SUPPLY

     5.1  Commercial Supply. Subject to the terms and conditions of this Section
          5, Omrix shall supply FFF with FFF's requirements for Product for
          commercial use in the US pursuant to this Agreement. Product shall be
          ordered and supplied at the Purchase Price (as defined below),
          according to the procedures outlined in this Section 5. Omrix will
          make reasonable commercial efforts to negotiate favorable pricing (at
          least fair market pricing) for the purchase by Omrix of US sourced
          recovered plasma.

     5.2  Annual Supply and Purchase Amounts.

          a.   In the Calendar Year that a BLA for the Product is approved by
               the FDA for use in humans with primary immune deficiency, Omrix
               agrees to sell to FFF and FFF shall purchase all Product produced
               by Omrix from US sourced recovered plasma, provided, however,
               that under no circumstances shall FFF be responsible for
               purchasing more than the pro rata share of *** grams of the
               Product based on the actual number of days from when the BLA is
               approved by the FDA until the end of the year in which the
               approval is received, unless Omrix has obtained FFF's prior
               written agreement that FFF will purchase any such excess Product.

          b.   Except as provided in Section 5.2.d below, each Calendar Year
               thereafter, Omrix agrees to sell to FFF and FFF shall purchase
               all Product produced by Omrix from US sourced recovered plasma,
               provided, however, that under no circumstances shall FFF be
               responsible for purchasing more than *** grams of the Product in
               a Calendar Year, unless Omrix has obtained FFF's prior written
               agreement that FFF will purchase any such excess Product.

          c.   In the Calendar Year that this Agreement is terminated or
               expired, Omrix agrees to sell to FFF and FFF shall purchase all
               Product produced by Omrix from US sourced recovered plasma
               purchased, provided, however, that under no circumstances shall
               FFF be responsible for purchasing more than the Pro Rata share of
               *** grams of the Product based on the actual number of days from
               January 1 of the year until the date on which this Agreement is
               terminated or expired, unless Omrix has obtained FFF's prior
               written agreement that FFF will purchase any such excess Product.

          d.   In the event that more than *** liters of recovered plasma
               sourced in the US is available to Omrix during a Calendar Year,
               then FFF will have the option to purchase the Product
               manufactured by Omrix from such excess recovered

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 6 of 29

<PAGE>

               plasma (the "Excess Product"). provided that Omrix will provide
               FFF with at least six (6) months prior written notice of the
               availability and Purchase Price applicable to the Excess Product.
               Omrix will provide FFF with evidence of the price to be paid by
               Omrix for the recovered plasma sufficient for FFF to verify the
               applicable Purchase Price for the Product. If within sixty (60)
               days of receipt of such written notice from Omrix of the quantity
               and price of the Excess Product FFF does not agree in writing to
               purchase such Excess Product, then the exclusivity granted to FFF
               under this Agreement shall not apply to such Excess Product.

          e.   Notwithstanding anything to the contrary in this Agreement, and
               in addition to any right to which Omrix may be entitled under
               this Agreement, in the event that FFF shall fail to order and
               purchase from Omrix the quantity of Product as required under
               this section 5 (i.e., *** grams, plus any higher amounts agreed
               to by FFF, including the Excess Product, if the purchase option
               is exercised by FFF), then Omrix shall have the right at its sole
               discretion to terminate FFF's exclusivity rights granted
               hereunder. Omrix shall exercise such right by issuing written
               notice to FFF; provided, however, such termination of exclusivity
               rights shall not affect the continued validity of those
               reasonably applicable remaining provisions of this Agreement and
               shall not preclude Omrix from the exercise of any other remedy
               available to Omrix under this Agreement or applicable law.

     5.3  Processing. Omrix, as the owner of the Technology and any improvements
          thereof, shall be responsible for Processing the Product, whether by
          itself or by third parties, subsidiaries or Affiliates, in accordance
          with the Specifications. Said Processing shall include, without
          limitation, all product labeling and other package inserts and
          materials required by the FDA. Omrix shall ensure that all services,
          facilities and goods used in connection with such manufacture comply
          with the applicable cGMPs in effect.

     5.4  Change in Processing. Omrix shall not implement any changes relating
          to the Product without providing FFF with 20-day prior written notice
          of such changes. A change is defined as any variation in the written
          procedures currently in place that: (a) impacts the regulatory
          commitments for the Product, (b) may require revalidation, (c) may
          materially affect the quality, purity, identity or strength of the Raw
          Materials or the Product, or (d) would necessarily result in changing,
          altering or modifying the Specifications, Handling Specifications,
          Testing Methods (defined below), sampling procedures, validation
          procedures or Master Batch Record relating to the Product. In the
          event that Omrix intends at any time to implement such a change, Omrix
          shall complete and bear all costs associated with implementing said
          change and performing the studies necessary to meet any and all
          requirements from the FDA (including, without limitation, the
          requirements of 21 CFR Sections 600.14 and 601.12) needed to approve
          such change, except that FFF may, at its sole discretion, complete and
          bear the costs of any clinical trials necessary to implement said
          change. Omrix shall supply at its expense all the Product required for
          such clinical trials.

     5.5  Forecasts. During the Term of this Agreement, Omrix shall, by November
          30th of each Calendar Year, provide FFF with a non-binding good faith
          forecast for the following Calendar Year, broken down into months, for
          the quantity of the Product that Omrix anticipates producing from US
          sourced recovered plasma. The forecast will be updated every other
          month, or more frequently, as otherwise updated by Omrix. The Parties
          acknowledge that the actual supply of the Product that Omrix is
          obligated to provide is subject to volumes provided under the DCI
          Contract.

     5.6  Orders for the Product. All FFF's orders for the Product shall be made
          pursuant to written purchase orders. Subject to the limitations set
          forth in Sections 5.2.a, 5.2.b,

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 7 of 29

<PAGE>

          5.2.c and 5.2.d above, FFF shall issue purchase orders (or if not
          issued, will be deemed to be issued) each calendar quarter, based upon
          Omrix's forecast provided in Section 5.5 above. All purchase orders
          must be faxed to Omrix at +972-3-535-0265. Any additional or different
          terms on FFF's purchase orders shall have no force or effect and shall
          be superseded by the terms of this Agreement. Purchase orders shall be
          signed by an authorized official of FFF and shall specify: (a) the
          purchase order number; (b) quantities; (c) requested delivery
          schedule; (d) preferred shipping method; and (e) exact "Ship to"
          address. Any additional or different terms on Omrix's written
          acceptance shall have no force or effect and shall be superseded by
          the terms of this Agreement. Once accepted by Omrix, FFF's purchase
          orders, including those for any excess Product as provided in Section
          5.2.d, shall be binding on Omrix to supply to FFF the quantities of
          the Product provided in the purchase orders. Omrix reserves the right
          to cancel, suspend, refuse, or delay any orders if FFF fails to make
          payment when due as required in Section 6.2 below or otherwise fails
          to comply with the terms and conditions of this Agreement.

     5.7  Delivery. Omrix shall ship the quantity of the Product ordered on the
          schedule set forth in Omrix's forecasts. Omrix shall be responsible
          for payment of the costs of shipping and insurance associated with the
          delivery of the Product to FFF. Omrix shall ship all Products F.O.B.
          FFF's designated facility in the US or at any alternative receiving
          location if agreed in writing by the Parties. For purposes of this
          Agreement, risk of loss in the Product shall pass to FFF at the time
          the Product is received by FFF.

     5.8  Title. Title to the Product to be delivered to FFF shall remain in
          Omrix until delivery of the Product to FFF as described in Section
          5.7. Thereafter title to the Product shall transfer to FFF.

     5.9  Conformity; Specifications; Quality Control.

          a.   All quantities of the Product supplied by Omrix pursuant to this
               Agreement will comply in all material respects with the
               Specifications and shall adhere in all material respects to all
               applicable governmental laws and regulations relating to the
               manufacture, packaging, sale, storage, and shipment of each
               shipment of the Product at the time it is shipped by Omrix
               hereunder.

          b.   Omrix shall conduct, or cause to be conducted, quality control
               testing of the Product prior to shipment, in accordance with the
               Specifications as are in effect and such other quality control
               testing procedures adopted by Omrix from time to time
               (collectively, the "TESTING METHODS"). The Testing Methods shall
               include all FDA required release testing and Omrix shall
               undertake all such tests. Omrix shall retain records pertaining
               to such testing. Each shipment of the Product hereunder shall be
               accompanied by a certified quality control protocol and
               certificate of analysis for each Batch of the Product therein as
               well as such customs and other documentation as is necessary or
               appropriate.

     5.10 Acceptance/Rejection. After receipt of a shipment of the Product,
          including documentation as provided in Section 5.9 above, FFF shall
          have ten (10) days to accept or reject the Product. Any such rejection
          should be based on a documented deviation from the Master Batch Record
          and shall be handled as hereafter set forth in Section 5.11.

     5.11 Rejection Procedures.

          a.   Should FFF reject any Batch pursuant to Section 5.10, and Omrix
               agrees that such rejection was justified, Omrix shall promptly
               credit FFF's account if the

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 8 of 29

<PAGE>

               invoice with respect to the Batch so rejected will have been paid
               by that time by FFF by virtue of Section 6.

          b.   Should FFF reject any Batch pursuant to Section 5.10, and should
               Omrix, after good faith negotiation, fail to agree that such
               rejection was justified, the Parties shall jointly appoint an
               independent third party to test samples of such Batch and to
               review any pertinent record and information developed by both
               Parties relating thereto to ascertain the validity of the
               rejection. The findings of such third party shall be binding upon
               both Parties. If the Product is found to meet the Specifications
               in all material respects, FFF shall pay the costs of such tests
               and shall be deemed to have accepted the Product as of the date
               such findings are published. If the Product is found not to meet
               Specifications in any material respect, Omrix shall pay the costs
               of such tests and shall promptly credit FFF's account.

          c.   Upon Omrix's receipt of a claim that a shipment or Batch thereof
               of the Product does not meet the Specifications, and Omrix agrees
               that such claim is justified, Omrix shall use commercially
               reasonable efforts to replace such shipment or Batch thereof with
               an additional shipment of the Product that does conform to such
               Specifications as soon as practicable.

     5.12 Inventory Management. Omrix shall maintain an inventory of the Product
          in accordance with Omrix's usual and customary inventory management
          practices that Omrix applies to its other therapeutic products, but
          sufficient to satisfy the requirements of this Section 5.

     5.13 Shortage of Supply.

          a.   Omrix shall notify FFF: (a) as promptly as possible, but in no
               event more than ten (10) days after Omrix's receipt of a purchase
               order from FFF as provided in Section 5.6, or (b) immediately
               upon becoming aware of Omrix's inability to supply the quantity
               of the Product to FFF that Omrix is required to supply hereunder,
               Omrix's inability to supply such quantities of the Product. In
               such event, Omrix shall implement all commercially reasonable
               efforts to remedy such shortage.

          b.   In the event of Omrix's inability to supply both FFF's
               requirements of the Product and Omrix's other requirements,
               including any third party requirements as of the date of this
               Agreement, for the Product due to force majeure or otherwise,
               Omrix shall first allocate the Product that Omrix has in
               inventory and that Omrix is able to produce among the quantities
               of all such requirements, so that FFF receives all of its
               required annual supply of Product, as determined from purchase
               orders and where purchase orders are not in place, from the
               forecasts, for the Product.

6.   PAYMENT

     6.1  Purchase Price. The purchase price for the Product supplied by Omrix
          to FFF pursuant to this Agreement is listed in Exhibit G ("PURCHASE
          PRICE"). The Purchase Price does not include any applicable taxes. FFF
          shall pay all US Taxes associated with the sale and delivery of
          Omrix's Product to FFF. The Purchase Price represents the net amount
          to be received by Omrix. If FFF shall be required to deduct, collect,
          withhold or pay such US Taxes, the sum payable to Omrix shall be
          increased as may be necessary so that after making all required
          deductions, Omrix receives the amount equal to the sum it would have
          received had no such deductions been made. Omrix shall pay all Other
          Taxes associated with the sale and delivery of Omrix's Product to FFF.

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL              Page 9 of 29

<PAGE>

     6.2  Invoices. Omrix shall invoice FFF for the Purchase Price for all
          Products upon shipment (i.e., when shipped from Omrix's plant). All
          invoices shall be due and payable within sixty (60) calendar days
          after receipt of the invoice by FFF, unless paid within 30 calendar
          days, which 30-day payments will receive a 2% discount. If FFF
          disagrees for any reason with the amount of an invoice submitted by
          Omrix, FFF shall notify Omrix in writing of such disagreement within
          thirty (30) calendar days of receipt of such invoice, and the Parties
          shall promptly attempt to resolve the difference. Omrix shall
          reference FFF's purchase order on all invoices.

     6.3  Late Payment Charge. Payments not received by Omrix when due are
          subject to a late payment charge at the lower of: (i) one and one half
          percent (1.5%) per month; and (ii) the maximum interested permitted
          under applicable law.

     6.4  Record Keeping. FFF shall keep full, true, and accurate records and
          accounts in accordance with generally accepted accounting practices in
          connection with this Section 6. These records and accounts shall be
          retained for a period of at least two (2) years following termination
          or expiration of this Agreement, or such longer period as required
          under applicable law. FFF shall allow Omrix representatives not more
          frequently than once each calendar year, upon five (5) business days
          notice and at reasonable intervals during normal business hours, to
          examine FFF's books, ledgers and records covering sales of the Product
          under this Agreement (the "AUDIT"). Omrix shall bear the expense of
          the Audit, provided, however, if any such Audit reveals that FFF has
          understated the amount of payments payment to Omrix pursuant hereto by
          an amount of more than five percent (5%) of the amount paid to Omrix
          during the period audited, in addition to any other rights and
          remedies available to Omrix under this Agreement, FFF shall pay, in
          additional to all payments contractually due and applicable interest
          thereon, all reasonable costs associated with the Audit.

     6.5  Financial Information. FFF shall provide to Omrix quarterly financial
          statements, annual audited financial statements, and any other
          information that may be reasonably requested by a credit or
          receivables insurance entity, or an entity extending credit to Omrix
          based upon receivables.

7.   TERMS AND CONDITIONS

     7.1  Term. The term of this Agreement shall be five (5) years, beginning on
          the Approval Date of the Product ("TERM").

     7.2  Condition Concurrent. Execution of the Supply and Distribution
          Agreement: Investigational Phase, attached hereto as Exhibit A, is a
          concurrent condition of execution of this Agreement.

     7.3  Processing, Changes to Processing. Omrix shall perform services under
          this Agreement in compliance with: (a) all applicable laws and
          regulations; (b) cGMP requirements; (c) the Omrix standard operating
          procedures in effect as of the date of this Agreement, including any
          written revisions as may later be required by either Party; and (d) in
          accordance with this Agreement, including the Specifications.

     7.4  Modifications to Specifications. Omrix will advise FFF in writing of
          any proposed or required modifications to the Specifications prior to
          their implementation.

     7.5  Adherence to Specifications. Omrix warrants that all Product shall be
          Processed in accordance with the Specifications. FFF warrants that,
          for the entire period the Product is in possession and under the
          responsibility of FFF (i.e., as from the time the Product is received
          by FFF until such time the Product has been successfully

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 10 of 29

<PAGE>

          distributed, marketed, offered for sale sold and/or imported by FFF to
          a third party or user), FFF shall comply with the Handling
          Specifications.

     7.6  Inspection by FFF. Omrix shall permit FFF representatives to enter
          Omrix's facility upon reasonable notice and at reasonable intervals
          during regular business hours for the purpose of making quality
          control inspections of the facilities used in manufacturing,
          receiving, sampling, analyzing, storing, handling, packaging, and
          shipping of the Raw Materials and the Product as FFF may reasonably
          request. FFF shall also have the right to have suitable
          representatives present in Omrix's plant to observe the Processing of
          the Product, storing, and shipping processes relevant to the Product.

     7.7  Inspection by Omrix. FFF shall permit Omrix representatives to enter
          FFF's facility upon reasonable notice and at reasonable intervals
          during regular business hours for the purpose of making quality
          control inspections of the facilities used in receiving, sampling,
          analyzing, storing, handling, packaging, and shipping of the Product
          as Omrix may reasonably request.

8.   CONFIDENTIAL INFORMATION

     8.1  Confidential Information. The Parties agree to protect the
          confidentiality of all "CONFIDENTIAL INFORMATION." For purposes of
          this Agreement, Confidential Information shall include all data and
          information generated or derived as the result of the work performed
          under this Agreement, the terms and existence of this Agreement, all
          Regulatory Filings, the Technology, and any and all materials or
          information in written, oral, or any other form concerning processes,
          methods, apparatus, specifications, products, materials, inventions,
          literature, patents (including applications and rights in either),
          finances, personnel, including any matters not technically or legally
          considered trade secrets, and any other information related to the
          business or activities of any disclosing Party which is not generally
          known to third parties. Confidential Information shall be designated
          "Confidential" when disclosed, provided that, if Confidential
          Information is not marked "Confidential" but, under the circumstances
          surrounding the disclosure, such information should in good faith to
          be treated as Confidential Information, the receiving Party shall
          treat such information as Confidential Information. Confidential
          Information does not include information that:

          a.   Has been in the public domain prior to such disclosure;

          b.   Becomes part of the public domain through no breach of an
               obligation by the receiving Party or its employees;

          c.   Is furnished to the receiving Party by others or by a third party
               who was or is not under an obligation of confidence to the
               disclosing Party at the time of the disclosure to the receiving
               Party;

          d.   Is or can be accurately documented to have been independently
               developed by the receiving Party, provided that information was
               not acquired directly or indirectly from the disclosing Party;
               however, the burden of proving that information disclosed by one
               Party to the other should not be considered "Confidential
               Information" shall be the receiving Party's; or

          e.   Is required to be disclosed pursuant to court order, legal
               proceeding or as required by law or regulation and the receiving
               Party first notifies the disclosing Party of the required
               disclosure.

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 11 of 29

<PAGE>

     8.2  Confidentiality Obligations. The Parties agree to not disclose,
          resell, transfer or use Confidential Information for any purpose other
          than performance of work under this Agreement, without the prior
          written consent of the disclosing Party. This provision shall remain
          in effect throughout the term of this Agreement and for a period of
          ten (10) years following the termination of this Agreement. The
          disclosing Party's Confidential Information provided to the receiving
          Party shall remain the exclusive property of the disclosing Party and
          shall be returned promptly to the disclosing Party upon written
          request or upon termination or expiration of this Agreement. Upon
          mutual agreement of the Parties, in lieu of returning Confidential
          Information, a receiving Party may destroy Confidential Information
          and provide written certification to the disclosing Party that such
          destruction took place.

     8.3  Publicity. During the term of this Agreement, neither Party shall,
          without the prior written consent of the other Party, use the other
          Party's name, logo, symbol or other images in connection with any
          products, promotion or advertising, nor disclose the existence or
          substance of this Agreement except as required by law.

     8.4  Permitted Disclosures. Notwithstanding the Sections 8.1 and 8.2, (i)
          the Parties may, to the extent necessary, disclose and use
          Confidential Information to prepare Regulatory Filings, to fulfill all
          regulatory requirements related to work performed under this Agreement
          including, without limitation, correspondence with the FDA, and to
          comply with securities and other agency regulations upon advice of
          counsel, and (ii) the Parties may, to the extent necessary, disclose
          Confidential Information to their affiliates, attorneys, and
          accountants, or to any potential investor or acquirer of a substantial
          part of such Party's business (whether by merger, sale of assets, sale
          of stock, or otherwise) that is bound by a written agreement to keep
          such terms confidential, or as may be required by law. Omrix agrees to
          provide FFF with prior notice if the terms of this Agreement will be
          disclosed by Omrix to an entity that directly competes in the
          manufacture or distribution of IGIV. Omrix's notice will state the
          identity of such competitor, and such information will be the
          Confidential Information of Omrix.

9.   WARRANTIES AND REPRESENTATIONS

     9.1  Warranties and Representations of Omrix. Omrix represents and warrants
          to FFF that:

          a.   Omrix is a company duly organized, validly existing and is in
               good standing under the laws of the jurisdiction of organization
               and has all necessary power to enter into and perform its
               obligations under this Agreement;

          b.   The execution, delivery and performance of this Agreement by
               Omrix has been duly authorized and approved by all necessary
               action and the Agreement is binding upon and enforceable against
               Omrix in accordance with its terms, except as such enforceability
               may be limited by bankruptcy, insolvency, fraudulent transfer,
               reorganization, moratorium and other similar laws and general
               principles of equity; and

          c.   Any document provided to FFF concerning the Product and the
               Master Batch Record is to the knowledge of Omrix, accurate.

     9.2  Warranties and Representations of FFF. FFF represents and warrants to
          Omrix that:

          a.   FFF is a corporation duly organized, validly existing and is in
               good standing under the laws of the jurisdiction of organization
               and has all necessary power to enter into and perform its
               obligations under this Agreement; and

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 12 of 29

<PAGE>

          b.   The execution, delivery and performance of this Agreement by FFF
               has been duly authorized and approved by all necessary corporate
               action and the Agreement is binding upon and enforceable against
               FFF in accordance with its terms, except as such enforceability
               may be limited by bankruptcy, insolvency, fraudulent transfer,
               reorganization, moratorium and other similar laws and general
               principles of equity.

10.  INDEMNIFICATION AND INSURANCE

     10.1 Indemnification by FFF. FFF shall defend, indemnify and hold harmless
          Omrix, its officers, agents, employees and Affiliates from any loss,
          claim, action, damage, expense or liability (including defense costs
          and attorneys' fees) finally imposed by court, arbitration, regulatory
          agency or settlement resulting from third party claims ("CLAIM") to
          the extent that the Claim is based on, arises out of, or is due to
          FFF's failure to perform its obligations under this Agreement or FFF's
          misconduct or negligence in the shipment, storage, handling,
          promotion, marketing, distribution and sale of the Product. Omrix
          shall promptly notify FFF of any such Claim coming to its attention
          and will cooperate with FFF in the defense of such Claim. If any such
          Claims or causes of action are made, Omrix shall be defended by
          counsel selected by FFF at FFF's expense, subject to Omrix's
          reasonable approval. Omrix reserves the right to be represented by its
          own counsel at its own expense.

     10.2 Indemnification by Omrix. Except for Claims for which FFF is obligated
          to indemnify under Section 10.1, Omrix shall defend, indemnify and
          hold harmless FFF, its officers, agents, employees and Affiliates from
          any Claim, to the extent that the Claim is based on, or arises out of,
          or is due to: (a) a defect of the Products; (b) the failure of the
          Product to meet Specifications; (c) a failure of Omrix to perform its
          obligations under this Agreement; or (d) infringement of any third
          party's intellectual property relating to the manufacturing,
          importing, use or sale of the Product. FFF shall promptly notify Omrix
          of any such Claim coming to its attention and will cooperate with
          Omrix in the defense of such Claim. If any such Claims or causes of
          action are made, FFF shall be defended by counsel selected by Omrix at
          Omrix's expense, subject to FFF's reasonable approval. FFF reserves
          the right to be represented by its own counsel at its own expense.

     If the Product is, or in Omrix's opinion, might be held to infringe as set
     forth above, Omrix may, at its option and cost, replace or modify the
     Product so as to avoid infringement, or procure the right for FFF to
     continue the use and sell the Product. The indemnification set forth in
     this section 10.2 shall be FFF's sole remedy and Omrix's sole liability
     arising out of Claims of infringement.

     10.3 Notices. In the event that either Party seeks indemnification (the
          "INDEMNIFIED PARTY") under the terms of this Section 10, the
          Indemnified Party shall notify the other Party (the "INDEMNIFYING
          PARTY"), in writing, of the action, suit, proceeding, claim,
          liability, demand or assessment giving rise to the claim for
          indemnification as soon as reasonably practicable after its assertion.
          The Indemnified Party shall permit the Indemnifying Party, at the
          Indemnifying Party's cost, to assume direction and control of the
          defense of the claim, and shall cooperate as requested (at the expense
          of the Indemnifying Party), in the defense of the claim. The
          Indemnified Party shall not settle or otherwise compromise any claims
          or suit without the prior written consent of the Indemnifying Party.

     10.4 Insurance. Each Party shall procure and maintain, at its own expense,
          in full force and effect at all times during which the Product are
          being sold pursuant to this Agreement, product liability insurance
          with respect to the Product, on the part of Omrix, and FFF, written by
          a responsible insurance carrier, Best Rated A, with a combined single
          limit of not less than ten million U.S. dollars (U.S. $10,000,000).
          Such insurance policy shall name both Parties hereto as additional
          insureds and will

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 13 of 29

<PAGE>

          provide for at least thirty (30) days prior written notice to the
          other Party of the cancellation or substantial adverse modification
          thereof. Each Party hereto shall deliver a certificate of such
          insurance to the other Party promptly upon issuance of the policy and
          shall, from time to time as reasonably requested by such other Party,
          furnish such other Party with evidence of the maintenance thereof. If
          any of the insurance policies described herein are written on a claims
          made basis, the applicable Party maintaining such insurance agrees
          either to (a) continue to purchase such coverage or (b) purchase an
          extended reporting period endorsement ("tail" insurance), in either
          instance for the entire Term, and for a period of five (5) years after
          the end of such Term.

     10.5 Waiver. Each Party hereby waives any claims against the other (whether
          found upon the indemnification provisions contained in this Agreement
          or otherwise) to the extent any such claim is covered by, and loss
          proceeds are paid to and received by such waiving Party, from the
          insurance either carried by and for the benefit of such waiving Party,
          and provided such waiver: (i) is not in violation of the policies of
          insurance under which such loss proceeds are so paid; (ii) does not
          invalidate such insurance; and (iii) does not disproportionately
          increase the premiums thereof.

11.  RECALLS AND WITHDRAWALS

     11.1 Implementation. If any Product must be recalled or withdrawn by reason
          of failure to meet any applicable Specifications, requirements of the
          FDA or any other requirements of law, FFF shall have the sole
          responsibility to effect the recall or withdrawal of the Product.
          Omrix shall cooperate as reasonably required in FFF's efforts, and
          shall notify FFF if it is determined by Omrix that such a recall or
          withdrawal is warranted based on Omrix's quality control findings.

     11.2 Costs. FFF shall reimburse Omrix for any costs reasonably expended by
          Omrix to effect the recall or withdrawal, unless the reason for the
          recall or withdrawal is due to Omrix's failure to Process the Product
          in accordance with the Specifications, a manufacturing error or
          omission, or the negligence of Omrix. In such case, Omrix shall
          reimburse FFF for any costs reasonably expended to effect the recall
          or withdrawal.

12.  RECORDS AND AUDITS

     12.1 Maintenance of Records. During the Term of this Agreement and for ten
          (10) years or such other period required by the FDA after the
          expiration date of any particular Batch of the Product manufactured by
          Omrix for FFF, Omrix shall maintain records and samples relating to
          such Batch(es) sufficient to substantiate and verify its duties and
          obligations hereunder, including but not limited to records of orders
          received, Raw Materials provided including the source and donor
          information of the human plasma, Product manufactured, work in
          progress, validation reports, Processing analyses and quality control
          tests, and the like.

     12.2 Regulatory Audits. Omrix shall be responsible for all routine
          stability testing and sample retention as required by the FDA. Omrix
          shall immediately inform FFF of all FDA or other regulatory audits
          pertinent to the Raw Materials, the Product or Specifications. Omrix
          shall inform FFF in advance of planned FDA or other regulatory audits
          as soon as the schedule therefor is known. Omrix shall provide FFF
          with copies of any regulatory letters or other documents issued by the
          FDA in connection with the audit or inspection within five (5) days of
          Omrix's receipt of such a document.

     12.3 Review of Records. Omrix shall allow FFF representatives, upon
          reasonable notice and at reasonable intervals during normal business
          hours, to enter Omrix's plant for

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 14 of 29

<PAGE>

          the purpose of taking inventories. Omrix shall further allow FFF
          representatives, upon reasonable notice and at such intervals as may
          be reasonably necessary, to examine and copy the records referenced in
          Section 12.1 and test the samples according to the procedures outlined
          in the Specifications during normal business hours for product
          liability, regulatory and quality control purposes.

13.  TERMINATION

     13.1 Termination by Either Party. Either Party shall have the right to
          terminate this Agreement by giving the other Party written notice if:

          a.   The other Party fails to perform or violates any material
               provision of this Agreement in any material respect, and such
               failure continues unremedied for a period of sixty (60) days
               after the date the notifying Party gives written notice to the
               defaulting Party with respect thereto; or

          b.   The other Party is declared insolvent or bankrupt by a court of
               competent jurisdiction, or a voluntary petition of bankruptcy is
               filed in any court of competent jurisdiction by the other Party,
               or the other Party makes or executes any assignment for the
               benefit of creditors, or a receiver is appointed to control the
               business of the other Party, or the other Party becomes subject
               to any proceedings under any bankruptcy or insolvency laws (which
               proceedings or appointment is not terminated within thirty (30)
               days).

     13.2 Termination by FFF for Cause. FFF may terminate this Agreement by
          giving Omrix written notice if during the Term of this Agreement, the
          Biologics License for the Product is suspended or revoked and cannot
          be reissued or reinstated without undue hardship to either Party.

     13.3 Termination by FFF without Cause. FFF may, upon sixty (60) days' prior
          written notice, terminate this Agreement subject to payment by FFF to
          Omrix of:

          a.   All purchases of the Product required to be made by FFF at the
               time of such termination pursuant to accepted Purchase Orders,
               plus

          b.   A sum equal to the unavoidable expenses for which Omrix will be
               liable because of such termination, including (i) amounts
               committed by Omrix in connection with the DCI Contract; provided,
               however, that if Omrix requires FFF to bear such costs in
               connection with such agreements, FFF will have the option to have
               such agreements assigned to FFF, subject to the approval of DCI,
               and Omrix shall have no obligations or liability after such
               assignment; and (ii) the proportionate part of the annual FDA fee
               paid by Omrix in connection with the marketing of the Product in
               the US on a pro-rata basis. The obligations of FFF under this
               Section 13.3 shall similarly apply if this Agreement is
               terminated by Omrix for cause under Section 13.1 above, in
               addition to any rights and remedies available to Omrix under this
               Agreement or law.

     13.4 Automatic Termination. This Agreement will automatically terminate if
          the Investigational Agreement is terminated prior to the Approval
          Date.

     13.5 Effect of Termination. This Agreement shall terminate in accordance
          with the time periods set forth in Sections 13.1, 13.2 and 13.3. On
          the date of termination or expiration of this Agreement, all rights
          and obligations granted under or imposed by this Agreement will cease
          and terminate, except as set forth in this Section 13.4 and Section
          28. Notwithstanding any other provision to the contrary contained
          herein,

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 15 of 29
<PAGE>

          such expiration or termination shall not affect any claim, demand,
          liability or right of a Party arising pursuant to this Agreement prior
          to the expiration or termination hereof.

     13.6 Transitional Matters.

          a.   Outstanding Purchase Orders. Upon expiration of this Agreement or
               earlier termination by Omrix or FFF:

               1.   Omrix, at its option, may cancel all unfilled orders; and

               2.   The due date of all outstanding invoices for the Product,
                    and the obligation to pay the sums detailed in Section 13.3
                    above, will automatically be accelerated so that they become
                    due and payable on the effective date of expiration or
                    termination, as the case may be, even if longer terms had
                    been provided previously.

          b.   Remaining Inventory. Upon termination of this Agreement by either
               Party or upon the expiration of this Agreement, FFF shall be
               entitled to sell any Product that remains in its inventory over a
               number of days determined by multiplying 1.2 times the average
               days of inventory which remains in FFF's inventory on the date
               the Agreement is terminated. After that time, FFF may not sell
               the Product.

14.  INTELLECTUAL PROPERTY

     14.1 Omrix Intellectual Property. All right, title and interest in and to
          all Omrix Intellectual Property shall be the sole and exclusive
          property of Omrix. Nothing in this Agreement should be construed to
          confer upon or grant FFF any right, title and interest therein.

          a.   Under this Agreement, "OMRIX INTELLECTUAL PROPERTY" includes the
               following as owned by Omrix: the Technology, as that term is
               defined in Section 2.22; patents, patent applications, patent
               disclosures and all related continuation, continuation-in-part,
               divisional, reissue, reexamination, utility model, certificate of
               invention and design patents, patent applications, registrations
               and applications for registrations; trademarks, service marks,
               trade dress, Internet domain names, logos, trade names and
               corporate names and registrations and applications for
               registration thereof; copyrights and registrations and
               applications for registration thereof; mask works and
               registrations and applications for registration thereof; computer
               software, data and documentation; inventions, trade secrets and
               confidential business information, whether patentable or
               nonpatentable and whether or not reduced to practice, know-how,
               manufacturing and product processes and techniques, research and
               development information, copyrightable works, financial,
               marketing and business data, pricing and cost information,
               business and marketing plans and customer and supplier lists and
               information; and copies and tangible embodiments thereof.

          b.   FFF expressly agrees that the name "Omrix," Omrigam NF and any
               related designs are the sole property of Omrix. It is further
               understood that there may be in the future other commercial names
               or marks identified with Omrix's products, and that the same are
               the property of Omrix. The said names, designs, and other marks
               are referred to collectively herein as the "OMRIX MARKS" which
               marks Omrix may, in its sole discretion, revise from time to
               time. FFF hereby acknowledges and agrees that Omrix shall retain
               ownership of all intellectual property rights in the Omrix Marks,
               including, but not limited to, any and all, modifications and
               derivatives thereto. All rights not expressly granted to FFF
               herein are reserved by Omrix.

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 16 of 29

<PAGE>

          c.   Upon termination or expiration of this Agreement, FFF shall
               return all Omrix Intellectual Property, provided that FFF may
               retain one copy of any documentation if necessary to comply with
               regulatory requirements, and that FFF may, in lieu of returning
               Omrix Intellectual Property, request permission from Omrix to
               destroy such property and provide written certification to Omrix
               of such destruction.

     14.2 Limited License. Omrix herby grants FFF the right and license to use
          Omrix Intellectual Property and Omrix Marks for the purpose of
          marketing, advertising, promoting, importing, selling and supporting
          the Product. The right and license granted hereunder is only in
          connection with the marketing, advertising, promoting, importing,
          selling and supporting the Product.

     14.3 FFF Intellectual Property. All right, title and interest in and to all
          FFF Intellectual Property shall be the sole and exclusive property of
          FFF. Nothing in this Agreement should be construed to confer upon or
          grant Omrix any right, title and interest therein.

          a.   Under this Agreement, "FFF INTELLECTUAL PROPERTY" includes:
               trademarks, service marks, trade dress, Internet domain names,
               logos, trade names and corporate names and registrations and
               applications for registration thereof; copyrights and
               registrations and applications for registration thereof; mask
               works and registrations and applications for registration
               thereof; computer software, data and documentation; inventions,
               trade secrets and confidential business information, whether
               patentable or nonpatentable and whether or not reduced to
               practice, know-how, manufacturing and product processes and
               techniques, research and development information, copyrightable
               works, financial, marketing and business data, pricing and cost
               information, business and marketing plans and customer and
               supplier lists and information; and copies and tangible
               embodiments thereof as owned by FFF.

          b.   Upon termination or expiration of this Agreement, Omrix shall
               return all FFF Intellectual Property, provided that Omrix may
               retain one copy of any documentation if necessary to comply with
               regulatory requirements, and that Omrix may, in lieu of returning
               FFF Intellectual Property, request permission from FFF to destroy
               such property and provide written certification to FFF of such
               destruction.

15.  INDEPENDENT CONTRACTORS

     It is not the intent of the Parties hereto to form any partnership or joint
     venture. Each Party shall, in relation to its obligations hereunder, act as
     an independent contractor, and nothing in this Agreement shall be construed
     to give such Party the power or authority to act for, bind or commit the
     other Party in any way whatsoever.

16.  LIMITED WARRANTY; LIMITATION OF LIABILITY

     16.1. Limited Warranty. Omrix warrants to FFF that the Omrigam NF will meet
          the specifications detailed in the BLA, the Specifications, and FFF's
          standard operating procedures (as reviewed and approved by Omrix) at
          the time of delivery of each shipment to FFF. FFF will inspect each
          such shipment within ten (10) days following receipt of the shipment
          (the "INSPECTION PERIOD") to determine whether the Omrigam NF complied
          with this warranty. FFF shall promptly notify Omrix within the
          Inspection Period if any particular shipment does not so comply with
          such warranty. If FFF does not deliver written notice to Omrix within
          the applicable Inspection Period of receipt of a shipment that FFF
          rejects such shipment because of a non-compliance with such

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 17 of 29

<PAGE>

          warranty, FFF will be deemed to have accepted the shipment. Any
          defective Omrigam NF shall, with Omrix's prior written authorization,
          be returned to Omrix, or any third party designated by Omrix, as set
          forth below, within the warranty period. Prior to returning any
          Omrigam NF, FFF must first obtain a Return Materials Authorization
          ("RMA") number from Omrix. Should the Omrigam NF prove defective prior
          to receipt by FFF, Omrix will remedy or replace, at its discretion,
          the defective Omrigam NF when it is returned to Omrix. If Omrix is
          unable to remedy or replace the Omrigam NF, it shall so notify FFF,
          and Omrix shall credit to FFF the amount paid by FFF to Omrix for such
          defective Omrigam NF, if any. This warranty shall not apply to the
          extent that Omrix determines the Omrigam NF has been subject to
          storage, use or other conditions caused by FFF not in accordance with
          the applicable specifications, or has otherwise been the subject of
          mishandling, misuse, neglect, alteration, or damage by FFF.

     16.2. WARRANTY EXCLUSION. EXCEPT AS EXPRESSLY SET FORTH ABOVE, THE OMRIGAM
          NF IS PROVIDED "AS IS", AND NO OTHER WARRANTIES, EITHER EXPRESSED OR
          IMPLIED, ARE MADE WITH RESPECT TO THE OMRIGAM NF, INCLUDING, WITHOUT
          LIMITATION THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A
          PARTICULAR PURPOSE. FFF's sole and exclusive remedy for any breach of
          the foregoing limited warranty will be, at Omrix's option, remedy or
          replacement of the Omrigam NF or refund the amount paid, if any. For
          the Omrigam NF that becomes defective after the warranty has expired,
          FFF may return it to Omrix for replacement after obtaining an RMA
          number. Provided FFF has received credit for the returned Product, FFF
          will be invoiced for the replacement Product upon shipment to FFF.

     16.3. EXCLUSION OF DAMAGES. EACH PARTY SHALL NOT UNDER ANY CIRCUMSTANCES BE
          LIABLE TO THE OTHER OR ANY CUSTOMER OR THIRD PARTY FOR ANY SPECIAL,
          INCIDENTAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING IN ANY
          WAY UNDER THIS AGREEMENT OR FROM DEFECTS IN OR USE OF THE OMRIGAM NF,
          AND UNDER ANY THEORY OF LIABILITY, EVEN IF A PARTY IS INFORMED IN
          ADVANCE OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT THE
          FOREGOING SHALL NOT APPLY TO DAMAGES AWARDED IN THE CASE OF PERSONAL
          INJURY OR DEATH TO THE EXTENT SUCH DAMAGES CANNOT BE DISCLAIMED UNDER
          APPLICABLE LAW, OR FOR BREACH OF CONFIDENTIALITY.

     16.4. CAP ON LIABILITY. TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW, IN
          NO EVENT WILL EITHER PARTY'S LIABILITY IN CONNECTION WITH OMRIGAM NF
          OR THIS AGREEMENT EXCEED $10,000,000. THESE LIMITATIONS APPLY TO ALL
          CAUSES OF ACTION IN THE AGGREGATE. THIS LIMITATION SHALL NOT APPLY TO
          AMOUNTS OWING FOR REQUIRED PURCHASES OF OMRIGAM NF BY FFF UNDER THIS
          AGREEMENT, INCLUDING AS REQUIRED UNDER THE DCI CONTRACT. THE FOREGOING
          LIMITATIONS IN THIS SECTION 16.4 SHALL NOT APPLY TO DAMAGES AWARDED IN
          THE CASE OF PERSONAL INJURY OR DEATH OR INFRINGEMENT UNDER SECTION 10.

17.  ASSIGNMENT AND DELEGATION; REORGANIZATION

     This Agreement may not be assigned by either Party without the prior
     written consent of the other Party, except that either Party shall be
     permitted to assign this Agreement, without the other Party's consent, to
     an Affiliate or a company acquiring all or substantially all of the first
     Party's relevant assets, voting stock or business to which this Agreement
     relates, upon written notice to the other Party. Such assignment shall be
     subject to the assignee agreeing in writing to assume the benefits and
     obligations of this Agreement. Any assignment made without prior written
     consent, if such consent is required, shall be wholly void and invalid. If
     either party is reorganized in such a manner

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 18 of 29

<PAGE>

     that a substantial portion of the assets of a party are transferred to an
     Affiliate, then such party shall require such Affiliate to guaranty the
     performance of such party's obligations under this Agreement. Anything to
     the contrary herein notwithstanding, each Party agrees that the right and
     obligations under this Agreement of the other Party may, from time to time,
     be exercised or performed, as the case may be, in whole or in part by
     Affiliates of such Party; provided that each Party shall remain liable for
     any such obligations delegated to its Affiliates.

18.  GOVERNING LAW AND VENUE

     This Agreement shall be governed by and construed and enforced in
     accordance with the laws of the State of New York without regard to
     conflict of laws principles. The UN Convention on Contracts for the
     International Sale of Goods shall not apply. Any action or proceeding
     arising out of this Agreement permitted to be brought in court under
     section 19.2 will be litigated in courts located in New York. Each Party
     consents and submits to the jurisdiction of any local, state, or federal
     court located in New York for such purpose.

19.  DISPUTE RESOLUTION

     19.1 Initial Efforts. The Parties agree to use their best efforts to
          resolve any controversy or claim arising out of or relating to this
          Agreement through good faith negotiations for a thirty (30) day
          period, unless otherwise agreed by the parties.

     19.2 Arbitration. The Parties agree that any dispute, controversy or claim
          that is not resolved under section 19.1, above, shall be settled by
          binding arbitration under the then current Commercial Arbitration
          Rules of the American Arbitration Association. Any such arbitration
          shall be conducted in the State of New York, in the English language.
          The arbitration shall be conducted by a sole arbitrator who shall be
          appointed by mutual agreement of the Parties. The Arbitrator shall be
          appointed by agreement of the Parties; provided, if the Parties fail
          to agree upon the Arbitrator within thirty (30) days of notice of
          arbitration provided by either Party, the Arbitrator shall be
          appointed by the American Arbitration Association. Upon rendering an
          award or a decision, the Arbitrator shall set forth in writing the
          basis of such award or decision. The Arbitrator's awards and decisions
          shall be final and binding upon the Parties. Judgment on the award or
          any other final or interim decision rendered by the Arbitrator may be
          entered, registered or filed for enforcement purposes in any court
          having jurisdiction thereof. The Parties agree that, any provision of
          applicable law notwithstanding, they will not request, and the
          arbitrator shall have no authority to award, punitive or exemplary
          damages against any Party. The costs of any arbitration, including
          administrative fees and fees of the arbitrator(s), shall be shared
          equally by the Parties, unless otherwise specified by the arbitrator.
          Each Party shall bear the cost of its own attorneys' and expert fees;
          provided that the arbitrator(s) may in their discretion award to the
          prevailing Party the costs and expense incurred by the prevailing
          Party in connection with the arbitration proceeding.

     19.3 Attorneys' Fees. If any arbitration or litigation is instituted to
          interpret, enforce, or rescind this Agreement, including but not
          limited to any proceeding brought under the United States Bankruptcy
          Code, the prevailing party on a claim will be entitled to recover with
          respect to the claim, in addition to any other relief awarded, the
          prevailing party's reasonable attorneys' fees and other fees, costs,
          and expenses of every kind.

20.  WAIVER

     A failure by one of the Parties to this Agreement to assert its rights for
     or upon any breach or default of this Agreement shall not be deemed a
     waiver of such rights nor shall any such waiver be implied from acceptance
     of any payment. No such failure or waiver in writing by any one of the
     Parties

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 19 of 29

<PAGE>

     hereto with respect to any rights shall extend to or affect any subsequent
     breach or impair any right consequent thereon.

21.  AMENDMENTS

     No alteration or amendment of this Agreement shall be valid unless agreed
     to in writing by both Parties.

22.  SEVERABILITY

     The Parties agree that it is the intention of neither Party to violate any
     public policy, statutory or common laws, and governmental or supranational
     regulations; that if any sentence, paragraph, clause or combination of the
     same is in violation of any applicable law or regulation, or is
     unenforceable or void for any reason whatsoever, such sentence, paragraph,
     clause or combinations of the same shall be inoperative and the remainder
     of the Agreement shall remain binding upon the Parties.

23.  FORCE MAJEURE

     Neither Party hereto shall be liable to the other in damages for, nor shall
     this Agreement be terminable by reason of, any delay or default in such
     Party's performance hereunder, if such delay or default is caused by
     conditions beyond such Party's control including, but not limited to, acts
     of God, war, insurrection, civil commotion, destruction of production
     facilities or materials by earthquake, fire, flood or storm, labor
     disturbances including strikes or lockouts, epidemic or failure of
     suppliers, public utilities or common carriers. Each Party hereto agrees to
     promptly notify the other Party of any event of force majeure under this
     Section and to employ all reasonable efforts toward prompt resumption of
     its performance hereunder when possible if such performance is delayed or
     interrupted by reason of such event.

24.  NOTICES

     24.1 All notices and other communications required or desired to be given
          or sent by one Party to the other Party shall be in writing, in the
          English language, and shall be deemed to have been given:

          a.   On the date of delivery, if delivered to the persons identified
               below,

          b.   Five (5) calendar days after mailing if mailed, with proper
               postage, by certified or registered airmail, postage prepaid,
               return receipt requested, addressed as set forth below,

          c.   On the date of receipt if sent by telex or telecopy, and
               confirmed in writing in the manner set forth in Section 24.1.b on
               or before the next day after the sending of the telex or
               telecopy, or

          d.   Two (2) business days after delivered to an internationally
               recognized overnight courier service marked for overnight
               delivery.

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 20 of 29

<PAGE>

     24.2 Notices shall be addressed to the following addresses:

TO FFF:                                 To Omrix:

FFF Enterprises, Inc.                   Omrix Biopharmaceuticals, Ltd
41093 County Center Drive               MDA Blood Center,
Temecula, CA 92651                      Tel Hashomer Hospital,
Attn: Patrick M. Schmidt, President     Tel Aviv 52621 Israel
                                        Attn: Robert Taub, President and CEO

Phone: (951) 296-2500                   Phone: +972 3 531 65 31
Fax: (951) 296-2565                     Fax: + 972 3 535 02 65
Email: pms@fffenterprises.com           Email: robert.taub@omrix.com

With a copy to:                         With a copy to:

Karen N. Winnett, Esq.                  Ronen Bezalel, Adv.
Preston Gates & Ellis LLP               Meitar, Liquornik, Geva & Leshem,
1900 Main Street Suite 600              Brandwein
Irvine, CA 92614                        16 Abba Hillel Silver Road
                                        Ramat Gan 52506
                                        Israel

25.  ENTIRE AGREEMENT

     This Agreement and the Investigational Agreement constitute the entire
     agreement between the Parties with respect to the subject matter hereof and
     supersede and replace all prior agreements, understandings, writings and
     discussions between the Parties. The Parties acknowledge and agree that
     neither of the Parties is entering into this Agreement on the basis of any
     representations or promises not expressly contained herein. It is agreed
     that no usage of trade or other regular practice or method of dealing
     between the Parties hereto shall be used to modify, interpret, supplement,
     or alter in any manner the terms of this Agreement. This Agreement may not
     be changed in any way except by an instrument in writing singed by both
     Parties.

26.  CAPTIONS

     The captions in this Agreement are solely for convenience of reference and
     shall not be used for purposes of interpreting or construing the provisions
     hereof.

27.  COUNTERPARTS

     This Agreement may be executed in one or more counterparts, each of which
     shall be deemed to be an original, but all of which together shall
     constitute one and the same agreement.

28.  SURVIVAL OF CERTAIN PROVISIONS

     The terms of any section which by their nature survives termination or
     expiration of this Agreement shall survive the termination or expiration of
     this Agreement, including without limitation Sections 4, 8 through 14, 16,
     17, 18, 19 and 23.

SIGNATURES, NEXT PAGE

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 21 of 29

PORTIONS OF THIS EXHIBIT MARKED BY AN *** HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
<PAGE>

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by
their duly authorized representatives, effective on this date first set forth
above.

OMRIX BIOPHARMACEUTICALS, LTD.          FFF ENTERPRISES, INC.

By: /s/ Robert Taub                     By:
    ---------------------------------       ------------------------------------
    Signature                               Signature
Name: Robert Taub                       Name: Patrick M. Schmidt
      -------------------------------   Title: President
Title:                                  Date: December 21, 2005
       ------------------------------
Date:
      -------------------------------

EXHIBITS
Exhibit A: Supply and Distribution Agreement: Investigational Phase
Exhibit B: Biologics License Application Approval Letter
Exhibit C: DCI Contract
Exhibit D: Handling Specifications
Exhibit E: Description of Omrix's Immune Globulin Intravenous
Exhibit F: Specifications
Exhibit G: Product Purchase Price

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 22 of 29

<PAGE>

                                    EXHIBIT A
            SUPPLY AND DISTRIBUTION AGREEMENT: INVESTIGATIONAL PHASE

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 23 of 29

<PAGE>

                                    EXHIBIT B
                  BIOLOGICS LICENSE APPLICATION APPROVAL LETTER

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 24 of 29

<PAGE>

                                    EXHIBIT C
                                  DCI CONTRACT

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 25 of 29

<PAGE>

                                    EXHIBIT D
                             HANDLING SPECIFICATIONS

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 26 of 29

<PAGE>

                                    EXHIBIT E
               DESCRIPTION OF OMRIX'S IMMUNE GLOBULIN INTRAVENOUS

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 27 of 29

<PAGE>

                                    EXHIBIT F
                                 SPECIFICATIONS

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 28 of 29

<PAGE>

                                    EXHIBIT G
                             PRODUCT PURCHASE PRICE

The Product Purchase Price shall be calculated as follows:

The per gram price is ***, based upon recovered plasma prices of (1) *** per
liter for recovered plasma frozen within 24 hours after phlebotomy ("24 Hour
Plasma") and (2) *** per liter for recovered plasma frozen within 72 hours after
phlebotomy ("72 Hour Plasma"). Assuming that the proportion of 24 Hour Plasma
and 72 Hour Plasma is 80% 24 Hour Plasma and 20% 72 Hour Plasma, the weighted
average per liter price would be *** per liter (the "Weighted Average Price").

The Weighted Average Price will change based upon (1) changes in the per liter
price paid by Omrix under its supply arrangements and (2) the then current
proportions of 24 Hour Plasma and 72 Hour Plasma.

Accordingly, the Purchase Price will be adjusted in an amount equal to *** of
the change in the Weighted Average Price per liter. For example, if the Weighted
Average Price per liter for recovered plasma increases/decreases by *** per
liter, then the corresponding increase/decrease in the Purchase Price per gram
will be ***.

FFF - Omrix Agreement: Commercial Phase   CONFIDENTIAL             Page 29 of 29<PAGE>
                                                                   Exhibit 10.13

                             PLASMA SUPPLY AGREEMENT

THIS PLASMA SUPPLY AGREEMENT (this "Agreement"), effective January 3, 2006
is made by Omrix Biopharmaceutical, Ltd., an Israeli company, with its
principal place of business located at MDA Blood Center, Tel Hashomer Hospital,
Tel Aviv 52621 Israel ("BUYER") and the DCI Management Group, LLC, a limited
liability company affiliated with Hutton Medical Services, LLC, having its
principal office at 1019 Fort Salonga Road, Suite 109, Northport, NY 11768
("SUPPLIER") (collectively the "parties").

SUPPLIER agrees to sell and BUYER agrees to purchase Recovered Plasma for
Fractionation and Frozen Recovered Plasma for Fractionation from SUPPLIER as
described in Exhibit B, which is attached hereto and, incorporated herein by
reference.

For purposes of this Agreement, "Frozen Recovered Plasma for Fractionation"
means recovered human plasma that has been frozen within 24 hours after
phlebotomy, and "Recovered Plasma for Fractionation" means recovered human
plasma that has been frozen within 72 hours after phlebotomy (collectively,
"Recovered Plasma"). During the Term (defined below) of this Agreement and for a
period of two years thereafter, BUYER shall not directly or indirectly purchase
any Recovered Plasma from any of the community blood banks, and/or hospitals
(collectively, "CBBs") set forth in Exhibit A attached hereto and made a part
hereof. This purchase restriction will cover any additional CBBs that, upon
agreement of the parties, are added to Exhibit A. This purchase restriction
shall not apply if SUPPLIER provides less than 50% of the Committed Volume, and
BUYER terminates this Agreement due to such material breach of SUPPLIER.

1.   PRICES AND VOLUMES - 2006

     SUPPLIER agrees to supply BUYER a minimum of *** liters of Recovered
     Plasma from December 1, 2005 through December 31, 2006 and in each of the
     four calendar years thereafter, ending December 31, 2010. However, SUPPLIER
     will make its best efforts to maximize the supply up to *** liters of
     Recovered Plasma per calendar year during the Term.

     The following is the agreed to price level for 2006. This would include
     Recovered Plasma that is collected from September 1, 2005 and stored until
     December 2005. This Recovered Plasma will be billed in the year 2005 and
     applied against the 2006 volumes, and will be delivered to BUYER no later
     than March 31, 2006.

     The price for DECEMBER 1, 2005 - DECEMBER 31, 2006 will be as follows:

     The first *** liters will be priced as follows:
     Frozen Recovered Plasma for Fractionation *** per liter
     Recovered Plasma for Fractionation *** per liter

PORTIONS OF THIS EXHIBIT MARKED BY AN *** HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
<PAGE>

                                       2

     For all volumes over the initial *** liters will be priced as follows:
     Frozen Recovered Plasma for Fractionation *** per liter
     Recovered Plasma for Fractionation *** per liter

     All prices are FOB CBB locations.

     SUPPLIER will notify BUYER in writing by no later than January 31, 2006 of
     the volume of Recovered Plasma (with a deviation of +/- 10%) that SUPPLIER
     commits to provide BUYER during 2006 (including December 2005). For each
     subsequent calendar year during the Term, SUPPLIER will notify BUYER in
     writing no later than November 15 of the prior year of the committed volume
     for such subsequent calendar year. The volumes referred in this paragraph
     are referred to as the "Committed Volumes."

     BUYER shall not be obligated to purchase more than *** liters per year.
     If an annual Committed Volume is less than *** liters, SUPPLIER shall
     continue during such year to make best efforts to provide *** liters,
     and BUYER shall be obligated upon written notice from SUPPLIER to purchase
     such additional volume, unless prior to receipt of any such notice BUYER
     notifies SUPPLIER in writing that BUYER does not, during such year, want to
     be obligated to purchase more than the Committed Volume, which notice shall
     be provided by BUYER no later than 90 days from SUPPLIER's notice setting
     forth the Committed Volume. Notwithstanding the foregoing, BUYER shall not
     be required to purchase more than the Committed Volume of the prior
     calendar year plus *** (not to exceed *** liters), provided, BUYER
     notifies SUPPLIER in writing 90 days before the American Association of
     Blood Banks (AABB) annual meeting that BUYER only intends to purchase a
     Committed Volume equal to that of the prior calendar year plus ***.

     In order to assist BUYER to qualify the Recovered Plasma for Thrombin,
     SUPPLIER will, within 30 days of the date of this Agreement, provide BUYER
     from each CBB with (i) 10 Recovered Plasma units which were separated and
     frozen after exactly 24 hours (i.e., Frozen Recovered Plasma for
     Fractionation) and (ii) 10 Recovered Plasma units which were separated and
     frozen after exactly 72 hours (i.e., Recovered Plasma for Fractionation).
     BUYER will pay for such units in accordance with the above pricing.

     Pricing for 2007 THROUGH 2010

     SUPPLIER will notify BUYER in writing (the "Price Notice") of the prices
     for Recovered Plasma applicable to the subsequent calendar year by no later
     than November 15th of each year preceding the applicable calendar year.
     SUPPLIER will keep BUYER updated on a regular basis on the status of price
     the negotiations between SUPPLIER and the CBBs. SUPPLIER will not raise
     prices to BUYER above the CPI (i.e., U.S. Consumer Price Index-All Urban
     Consumers, U.S. City Average, as published by the Bureau of Labor
     Statistics,

<PAGE>

                                       3

     U.S. Department of Labor) without BUYER's written consent. The prices set
     forth in a Price Notice for a calendar year will be based on current market
     conditions. If the current market price is above the CPI adjusted price,
     then the parties will mutually agree on the price to be charged. If there
     is a disagreement about the price determined by SUPPLIER based upon current
     market conditions, the parties will follow Section 14, Disputes, and the
     price determined under Section 14, Disputes, will apply retroactively to
     all purchases made by BUYER of the Committed Volume for such year. If at
     anytime, a requirement of a regulatory agency (e.g., IGIV specification for
     Omrigam) results in BUYER not being able to use a certain variety of
     Recovered Plasma (i.e., Frozen Recovered Plasma for Fractionation or
     Recovered Plasma for Fractionation) to produce and distribute BUYER's
     products, then, upon written notice to SUPPLIER, BUYER shall no longer be
     required to purchase such Recovered Plasma from SUPPLIER.

     Orders for Recovered Plasma may be submitted by BUYER or BUYER's
     affiliates.

2.   TERM

     The term of this Agreement will be begin on December 1, 2005 and end
     December 31, 2010, unless terminated sooner as provided under this
     Agreement (the "Term"). At the end of the Term, the contract can be
     extended with the mutual agreement of the parties for 3 years.

3.   PAYMENT

     Net 30 days from date of invoice, which may be issued any time after
     shipment. All payments will be wire transferred to a mutually agreed
     account. Late payment would be charged interest at 12% per annum or 1% per
     month.

     SUPPLIER shall invoice BUYER and BUYER shall remit payment via wire
     transfer to:

     DCI Management Group, LLC
     Wachovia Bank - NA
     202 Mamaroneck Ave.,
     White Plains, New York, 10601
     ABA #031201467,
     Account #2000011693161.

     Wherever there is provision in this Agreement for a credit to BUYER, if
     such credit cannot be fully applied to invoices within 60 days of when the
     credit arises, then such credit, or remaining balance, shall be paid by
     SUPPLIER to BUYER at the end of such 60-day period.

<PAGE>

                                       4

4.   SPECIFICATIONS

     The CBBs will follow specifications as per attached Omrix specifications
     (see Exhibit B attached) and all Applicable Laws (collectively,
     "Specifications").

     Any exceptions to the Specifications must be mutually agreed to in advance
     and in writing. Unless otherwise agreed in writing by the parties, CBBs
     will follow all F.D.A. 'lookback' (lookback) and post-donation
     requirements. BUYER will supply exact address to send lookback
     notifications and the parties will mutually agree to procedures covering
     all lookback events, which procedures will include a full credit to BUYER
     for any Recovered Plasma (i) that did not meet Specifications at the time
     of collection; (ii) where there was a subsequently identified testing issue
     after collection; or (iii) the unit was recalled by the CBB. All CBBs have
     received all necessary regulatory approvals and permits under "Applicable
     Law," including, but not limited to, F.D.A. approval, required state
     licensing, and Clinical Laboratory Inspection Act (CLIA) licensure and
     approval. SUPPLIER agrees to work with the CBBs to make reasonable efforts
     to assist BUYER to comply with requirements of the Israeli Ministry of
     Health relating to the import of the Recovered Plasma into Israel. CBBs
     will be required to sign the BUYER's Short Supply Agreement, attached
     hereto as Exhibit C, which form may be changed by BUYER from time to time.
     The CCBs can collect Recovered Plasma before the actual Short Supply
     Agreement date (but not earlier than September 1, 2005) as long as they
     certify that the Specifications were being followed on the date of the
     earliest bleed. As used herein, "Applicable Law" shall mean all applicable
     federal, state and local laws, rules, regulations and requirements of
     governmental and regulatory authorities, including, but not limited to, the
     FDA investigational new drug (IND) guidelines, Title 21 of the U.S. Code of
     Federal Regulations Part 640, as amended, cGMP (defined in Exhibit B), the
     Clinical Laboratory Inspection Act (CLIA) and such other applicable laws,
     regulations, requirements, and guidelines.

5.   TRANSPORTATION

     BUYER will supply shipping boxes for Recovered Plasma and will be
     responsible for their distribution to the CBBs. Desired size would allow
     16-20 units per box. If required, SUPPLIER can purchase these boxes and
     charge BUYER the cost of purchasing and transporting the boxes to the CBBs.
     Unless otherwise agreed in writing, shipments will be accompanied by
     documentation as required by the FDA, Specifications and Applicable Law,
     and as may otherwise be specified by BUYER. The shipping boxes shall bear
     external labeling which correlate to the donation list. Each bag of
     Recovered Plasma in a shipping box shall bear, in addition to other
     required labels, a bar code label of the donation number.

     The parties will agree on a shipping schedule that will allow all CBBs to
     ship every 2-4 weeks depending on size of the CBB and freezer capacity at
     the CBB.

<PAGE>

                                       5

     SUPPLIER will provide BUYER each month with a rolling three month forecast
     of the anticipated shipping schedule (total by month and type)).

     BUYER assumes title to the Recovered Plasma when it is accepted on BUYER's
     behalf by BUYER's designated carrier. All transportation charges are for
     BUYER's account.

     If a shipment of any Recovered Plasma or any portion thereof fails to
     conform to the Specifications or is otherwise not as warranted, then BUYER
     shall have the right to reject such non-conforming shipment or portion
     thereof. BUYER shall give written notice to SUPPLIER of its rejection
     hereunder, setting forth in detail the basis of the rejection, within
     forty-five (45) days after receipt at BUYER's facility, specifying the
     grounds for such rejection. The nonconforming shipment or portion thereof
     shall be held for SUPPLIER's disposition, or shall be returned to SUPPLIER,
     or destroyed if required by Applicable Law, in each case at SUPPLIER's
     expense, as directed by SUPPLIER. BUYER shall not be obligated to buy or
     pay for any shipment which does not comply with the Specifications, or is
     otherwise not as warranted. BUYER shall receive a full credit for any
     rejected shipment, which shall include BUYER's shipping costs to BUYER's
     facility. Upon a request from BUYER, any CBB that is the source of a
     non-conforming shipments shall be removed from Exhibit A.

6.   PRODUCT

     As used herein, "Recovered Plasma" shall mean "Plasma for Further
     Manufacturing" (Frozen Recovered Plasma and Recovered Plasma for further
     manufacturing) as defined by the regulations of the Food and Drug
     Administration (Title 21 Code of Federal Regulation 606.3 et. seq.), the
     American Association of Blood Banks manual, and the Specifications set
     forth in Exhibit B, now or hereafter in effect, and shall have been
     collected from volunteer homologous donors and processed pursuant to the
     Applicable Laws.

     All Recovered Plasma shall be certified by the CBBs to be in compliance
     with the Specifications, including, without limitation, having been tested
     for viral markers/NAT-PCR, as listed in Exhibit B. This Agreement is
     subject to CBB compliance with any and all test requirements currently and
     hereafter mandated by Applicable Law.

     SUPPLIER warrants and covenants that all Recovered Plasma delivered under
     this Agreement meets the Specifications contained in Exhibit B. BUYER
     assumes full responsibility for the storage, handling, processing,
     manufacturing, sale and use of the Recovered Plasma upon SUPPLIER's
     delivery to BUYER.

     BUYER shall only be responsible for any loss, destruction or damage to the
     Recovered Plasma at all times that such Recovered Plasma is in the care,
     custody and control of BUYER (including its agents and contractors).

<PAGE>

                                       6

     Notwithstanding any other agreements, each party agrees to hold harmless
     and indemnify the other party (including its affiliates, and each of their
     respective directors, officers, agents, and employees) against, and
     reimburse the indemnitees for, any and all claims, demands, actions, causes
     of action, losses, judgments, damages, costs and expenses (including
     reasonable attorney's fees) arising out of any claim against an indemnitee
     (i) in respect to bodily injury, death, and property damage to the extent
     arising from the acts or omissions of the indemnifying party, (ii) a
     party's violation of any Applicable Law; or (iii) any breach by a party of
     any of its representations, warranties, covenants or agreements in this
     Agreement. At the indemnified party's option, the indemnifying party shall
     also defend the indemnified party, and in such case, shall have sole
     control of the defense and settlement, provided that any settlement must be
     agreed to by the indemnified party.

     This obligation to indemnify is conditional upon the party seeking to be
     indemnified providing the other party with prompt written notice of any
     claim or action for which the first party seeks to be indemnified. Each
     party agrees to cooperate in providing information necessary to defend
     against any such legal liability.

     Each party agrees to maintain general and professional liability insurance,
     each in the amount of at least One Million dollars ($1,000,000) combined
     single limit, and to provide copies to the other party of certificates of
     such insurance upon request.

     BUYER and SUPPLIER, on their own behalf, acknowledge and agree that each
     shall inform the other of any third party claim related to this Agreement
     and involving the other party as soon as it becomes aware of such claim.

7.   OTHER

     All notices, communications, demands, and payments required or permitted to
     be given or made hereunder or pursuant hereto shall conclusively be
     presumed for all purposes of this Agreement to be given or made by
     certified mail or overnight courier service, addressed as follows:

          BUYER:      Omrix Biopharmaceuticals, Ltd
                      MDA Blood Center, Tel Hashomer
                      Hospital, Tel Aviv 52621 Israel
                      Attn: Robert Taub
                      President and CEO

          SUPPLIER:   DCI Management Group, LLC
                      1019 Ft. Salonga Road

<PAGE>

                                       7

                      Suite 109
                      Northport, NY 11768
                      Attn: Ira London
                      Vice President of Marketing

Each party will appoint a contact person to handle all logistics and quality
issues.

8.   GOVERNING LAW

     Without giving effect to the conflict of law provisions, this Agreement
     will be governed and construed in accordance with the laws of the State of
     New York.

9.   TERMINATION FOR DEFAULT

     Either party may terminate this Agreement by written notice to the other
     party if such other party materially fails to perform or materially
     defaults in any manner in the performance of this Agreement in accordance
     with its terms, and fails to cure any such breach after receiving a "Show
     Cause Notice" identifying the failure, and providing thirty (30) days to
     cure the failure or nonperformance. However, if the claimed failure to
     perform or other default is the subject of a bona fide dispute between the
     parties, then the parties agree to refer the dispute to the informal
     dispute escalation process under Section 14 of this Agreement and that the
     30-day cure period shall be waived pending the outcome of that process.
     BUYER may terminate this Agreement upon written notice if a regulatory
     action or decree prevents BUYER from performing the manufacture and/or
     distribution of the end products (i.e., Omrigam NF) derived from the
     Recovered Plasma. In the event of a termination, the parties agree to cease
     all further purchases. The BUYER's liability to SUPPLIER in the event of
     termination will continue only with respect to goods and/or services
     received and accepted within thirty (30) days after the effective date of
     termination.

     Neither party will be liable for failure to perform due to unforeseeable
     causes beyond such party's control and without such party's fault or
     negligence, such as acts or omissions by the other party, fires, floods,
     epidemics, quarantine restrictions, strikes, freight embargoes, war, an act
     of governmental or quasi-governmental authorities, restrictions of law or
     of a court of competent jurisdiction.

     The rights and remedies of either party provided in this paragraph are not
     exclusive and are in addition to any other rights and remedies provided by
     law or under this Agreement.

<PAGE>

                                       8

10.  INDEPENDENT CONTRACTOR

     SUPPLIER is furnishing its services hereunder as an independent contractor,
     and nothing herein will create any association, partnership or joint
     venture between the parties hereto, or any employer-employee relationship.

11.  CONFIDENTIALITY

     Each party may designate any or all information, data, written and/or
     verbal communications developed, accessed, provided, or referenced during
     the performance of this Agreement as Confidential.

     The BUYER and SUPPLIER acknowledge and agree that if during the Term of
     this Agreement such information is designated confidential and is disclosed
     by one party to the other, each party will hold all such confidential
     information in the strictest confidence as a fiduciary and will not
     voluntarily sell, transfer, publish, disclose, display or otherwise make
     available to any third persons such confidential information or any portion
     thereof without the express written consent of the other party or use such
     information except in the performance of this Agreement. The BUYER and
     SUPPLIER will each use their best efforts to protect the confidentiality of
     all such information consistent with the manner in which they protect their
     most confidential business information.

     For the purposes of the Agreement, confidential information includes all
     Agreement terms and conditions, and such other information identified as
     Confidential prior to disclosure. Notwithstanding the foregoing, (i) a
     party may disclose the terms of this Agreement to securities and other
     regulatory agencies as may be advised by legal counsel, (ii) to affiliates,
     attorneys, accountants and consultants, or to any potential investor or
     acquirer, provided all are bound by confidentiality obligations, and (iii)
     BUYER may disclose this Agreement to a purchaser of the products produced
     by BUYER from the Recovered Plasma.

12.  TITLE TO GOODS

     SUPPLIER warrants and represents that clear and unrestricted title for all
     goods or products under this Agreement will pass to the BUYER upon
     acceptance by BUYER as defined in Section 5; however, BUYER's
     responsibilities for all goods and products provided hereunder arise with
     BUYER's taking possession of such goods and products.

13.  SOLE AGREEMENT/AMENDMENTS

     This Agreement constitutes the entire agreement between the parties hereto
     concerning the subject matter contained in it, and no amendment,
     modification or

<PAGE>

                                       9

     waiver of any of the terms and conditions hereof will be valid unless in
     writing and executed by both parties. Any prior verbal or written
     agreements are not considered a part of this Agreement.

14.  DISPUTES

     To the extent that there are disputes with respect to performance,
     including payments, under this Agreement, such disputes are not cause for
     the SUPPLIER to stop work or BUYER to stop payment under the Agreement, but
     will be resolved in due course to the extent possible in accordance with
     this section.

     The parties to this Agreement will attempt to resolve any problem or
     dispute arising out of, or related to, this Agreement through good faith
     consultation in the ordinary course of business. In the event that any
     problem or dispute is not so resolved, either party may upon written notice
     ("Notice") to the other request that the matter be referred to senior
     management officers within each respective organization with express
     authority to resolve the problem or issue but who are not immediately
     responsible for the matters contemplated by this Agreement. Within ten days
     of the Notice of the dispute, such representatives will meet or confer at
     least once in good faith to negotiate a resolution.

     If the representatives are unable to resolve the problem or dispute within
     thirty (30) days of the Notice, either party may take the matter to the
     Dispute Resolution Procedure set forth below.

     Dispute Resolution Procedure: If any problem or dispute arising out of or
     related to this Agreement is not resolved by the parties in the above
     described manner, at the request of either party, the matter will be
     submitted to binding arbitration conducted in New York City, by a sole
     arbitrator in the English language, and in accordance with the rules and
     procedures set forth by American Arbitration Association. The sole
     arbitrator shall be appointed by agreement of the parties. In the event the
     parties fail to agree upon the appointment of the sole arbitrator within
     thirty (30) days after a notice of arbitration is given by either party to
     the other, then the arbitrator shall be selected and appointed by the
     American Arbitration Association. The arbitration award and/or
     determination shall be final and binding and judgment may be entered
     thereon in any court of competent jurisdiction.

15.  ORDER OF PRECEDENCE

     In the event of a conflict between the terms of this Agreement, or any
     amendments hereto executed in accordance with Section 13, the terms of the
     amendment govern.

<PAGE>

                                       10

16.  SEVERABILITY

     Each paragraph and provision of this Agreement is severable from the entire
     Agreement, and if any provision is declared invalid, the remaining
     provisions will remain in effect.

17.  WARRANTIES

     Each party hereby represents, warrants and covenants that:

     (a) All services performed and products supplied under this Agreement will
     conform to the requirements of this Agreement, the Specification, and all
     Applicable Laws.

     (b) It is duly organized, validly existing and in good standing under the
     laws of the jurisdiction in which it was organized, (b) this Agreement,
     when executed and delivered by it, will be the legal, valid and binding
     obligation of it, enforceable against it in accordance with its terms, (c)
     the execution, delivery and performance of this Agreement by it do not and
     will not (i) conflict with, or constitute a breach or default under, its
     charter documents or any material agreement, contract, commitment, or
     instrument to which it is a party or (ii) require the consent, approval or
     authorization of, or notice, declaration, filing or registration with, any
     third party or any governmental or regulatory authority, and (d) it has not
     previously granted and will not grant any rights to any third party which
     are, nor contract with any third party in any manner which is, inconsistent
     with the rights granted herein.

18.  BANKRUPTCY

     This Agreement may be terminated by either party upon serving notice in the
     event that the other party shall be or become insolvent, shall cease doing
     business as a going concern, make an assignment for the benefit of its
     creditors, admit in writing its inability to pay its debts as and when they
     fall due or in the event that there are any proceedings instituted by or
     against it in bankruptcy or under the insolvency laws or for receivership
     or dissolution which are not frivolous or vexatious proceedings or not
     dismissed within thirty (30) days from commencement of such proceedings.

19.  ASSIGNMENT

     This Agreement shall not be assignable by any party without the prior
     written consent of the other party, except that (i) either party shall be
     permitted to assign this Agreement, without the other party's consent, to
     an affiliate or a company acquiring all or substantially all of the first
     party's assets, voting stock or business to which this Agreement relates,
     and (ii) BUYER shall be permitted to assign this

<PAGE>

                                       11

     Agreement, all upon written notice to the other party. Such assignment
     shall be subject to the assignee agreeing in writing to assume the benefits
     and obligations of this Agreement. Any assignment made without prior
     written consent, if such consent is required, shall be wholly void and
     invalid.

20.  RECORDS

     SUPPLIER shall maintain complete and accurate records of and supporting
     documentation for supply of the Recovered Plasma to BUYER, for a period of
     two (2) years following termination of this Agreement, or other longer
     period required under this Agreement or Applicable Laws. SUPPLIER agrees to
     provide BUYER with documentation and other information as may be reasonably
     requested by BUYER to verify accuracy and compliance with the provisions of
     this Agreement.

21.  SURVIVAL

     Any provisions of this Agreement that, in order to fulfill the purposes of
     such provisions, need to survive the termination or expiration of this
     Agreement, shall be deemed to survive for as long as necessary to fulfill
     such purposes.

     IN WITNESS WHEREOF, the parties hereto caused this Agreement to be executed
     by their representatives duly authorized as of the day and year first above
     written.

DCI MANAGEMENT GROUP, LLC               OMRIX BIOPHARMACEUTICALS, LTD

/s/ Ira London                          /s/ Robert Taub
-------------------------------------   ----------------------------------------
Ira London                              Robert Taub
Vice President of Marketing             President and CEO

Date:                                   Date:
      -------------------------------         ----------------------------------

<PAGE>

                                       12

EXHIBIT A - COMMUNITY BLOOD BANKS SUPPLYING PLASMA TO BUYER

EXHIBIT A

COMMUNITY BLOOD BANKS SUPPLYING PLASMA TO BUYER

1.   LIFESOUTH, GAINESVILLE, FL

2.   BLOODNET, LAKELAND, FL

3.   MEDIC, KNOXVILLE, TN

4.   ANMED, ANDERSON, SC

5.   DAK-MINN, GRAND FORKS, ND

6.   SIOUX VALLEY, SIOUX FALLS, SD

7.   LANE, EUGENE, OR

8.   NWFL, PENSACOLA, FL

9.   SHEPEARD, AUGUSTA, GA

10.  PIEDMONT, SPARTANBURG, SC

11.  SOUTH TEXAS BLOOD AND TISSUE CENTER, SAN ANTONIO, TX

12.  CHAMPLAIN, PLATTSBURGH, NY

13.  USBB, MIAMI, FL

14.  BLOOD ASSURANCE, CHATTANOOGA, TN

15.  BC NC WISCONSIN, WAUSAU, WI

16.  SUNCOAST COMMUNITIES BLOOD BANK, SARASOTA, FL

17.  BLOOD BANK OF SAN BERNARDINO AND RIVERSIDE COUNTIES, SAN BERNARDINO, CA

18.  COMMUNITY BLOOD BANK, RANCHO MIRAGE, CA

19.  UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, HOUSTON, TX

This is a preliminary listing of CBBs. Additional CBBs will be added as
necessary to increase yearly volumes, upon the mutual written agreement of the
parties. Such additions, upon mutual written agreement, may be made by SUPPLIER
at any time during the Term of this Agreement.

<PAGE>

                                       13

SUPPLIER shall provide BUYER access to all documents relating to its and the
CBBs' performance under this Agreement to the extent required by Applicable Law
or for BUYER to comply with Applicable Law. SUPPLIER shall allow and arrange
access by BUYER during normal business hours to all such documents and to its
and the CBBs' facilities for purposes of inspections or other requests for
access by BUYER in accordance with Applicable Law, and to confirm compliance
with the terms of this Agreement. Inspections by BUYER will be made upon
reasonable prior notice. The inspection rights in this Exhibit shall be
authorized in SUPPLIER's agreements with the CBBs. Any CBB that is found not to
conform to Applicable Law or the Specifications shall be removed from this
Exhibit A.

If any CBB is closed as a result of regulatory sanctions or receives a warning
letter or consent decree from the FDA or any other governing entity or if
SUPPLIER or such CBB is found to have compliance problems that might affect the
quality of the Recovered Plasma (each a "Triggering Event"), SUPPLIER must
notify BUYER immediately, and in any event not later than 5 business days after
SUPPLIER learns of such Triggering Event, consent decree or problem. Following
any such Triggering Event, based on the substance of the Triggering Event
(related to the quality of the plasma) SUPPLIER will recall all stocks of
Recovered Plasma held by BUYER at such time and issue a credit to buyer.
Additionally, if any CBB is found by BUYER to be deficient in its compliance
with the Specifications or Applicable Law, SUPPLIER will have thirty (30)
business days to provide, in writing, a corrective action plan ("CAP")
acceptable to BUYER. No Recovered Plasma will be shipped to BUYER from such CBB
until the CAP was successfully implemented and such CBB was approved by BUYER to
be clear of the deficiency declared as provided above. If the CAP is
unacceptable to BUYER or if a CAP cannot be implemented for any CBB within
ninety (90) days after the announcement of such a deficiency, then, at BUYER's
option, this Agreement, including the Recovered Plasma volumes, can be modified
to eliminate such CBB.
<PAGE>

                                       14

EXHIBIT B - OMRIX PRODUCT SPECIFICATIONS

                         HUMAN PLASMA FOR FRACTIONATION
                RECOVERED PLASMA SPECIFICATIONS AND REQUIREMENTS

DEFINITION:

As used herein, "Plasma" shall mean "Plasma for Further Manufacturing" (Frozen
Recovered Plasma and Recovered Plasma for further manufacturing) as defined by
the regulations of the Food and Drug Administration (Title 21 Code of Federal
Regulation 606.3 et. seq.), the American Association of Blood Banks manual, and
the applicable items set forth in this Exhibit B now or hereafter in effect, and
shall have been collected from volunteer homologous donors and processed
pursuant to the regulations applicable thereto.

Frozen Recovered Plasma for Fractionation; i.e. separated from the cellular
elements and frozen by cooling rapidly to minus 20 degrees C (-20 degrees C)
within 24h or Recovered Plasma for Fractionation separated from the cellular
elements and frozen by cooling rapidly to minus 20 degrees C (-20 degrees C)
within 72h.

The plasma may contain cryoprecipitate fraction or be cryo-depleted.

The plasma meeting these definitions will comply with all requirements as they
may be updated from time to time by the FDA regulations.

All blood donations are collected by FDA licensed blood donor centers or blood
banks.

Anticoagulant solutions, plasma containers and labels must comply with the CFR
regulations.

DONOR SELECTION, BLOOD COLLECTION AND RECORD MAINTENANCE

Authorizations of the blood donor centers/ blood banks as well as procedures of
selection of donors and blood collections are according to the regulations and
guidelines of the FDA/CFR.

STORAGE AND SHIPMENT

The plasma is maintained at or below -20 degrees C during storage and
transportation according to CFR regulations. Documentation of temperature
monitoring is required during shipping.

The Plasma received by Omrix must be less than 12 months from the date of
donation.

<PAGE>

                                       15

VIRAL MARKER & NAT-PCR TESTS

Each donation must be individually tested and found non-reactive/ negative for:

HBsAg
antibodies to HCV and HIV 1/2.

HTLV I/II
All donors are tested for indirect Antiglobulin and have been found negative.

All units are tested and found negative for Syphilis.

PCR/NAT tests for HCV and HIV will be performed by FDA approved mini pool
testing (pools of 16 or 24 according to manufacturers approved methodology) and
found negative. Units found to be positive shall be removed from the shipment.
Additional PCR/NAT (e.g. Parvao B19) testing will be performed if required by
FDA--if FDA requires additional PCR/NAT testing CBB will take necessary action
to meet FDA standards.

All the tests must be performed in FDA approved laboratories.

Supplier shall provide Buyer with a copy of the directional insert for each type
of test kit used in testing and a notification of changes of test kit types.

The kit details should be provided including Name, Manufacturer, Generation and
License Number.

All testing kits used for plasma donation testing must be licensed by the US
FDA. Each test kit must be validated in the testing lab and a report provided.
This shall be interpreted to mean, the Blood Centers supplying Recovered Plasma
Products to Omrix will use licensed FDA test kits and will follow test kit
manufacturers directional insert for testing procedure, including use of
controls. The Blood Center testing lab will employ the use of external controls
and participate in proficiency testing programs for those related viral markers
as available. The testing lab has not validated the test kit, the FDA licenses
the test kit and to our understanding releases each lot from licensed
manufacturer, (i.e. Abbott/ Ortho) prior to release of lot numbers for Blood
Bank usage. Any changes to the testing laboratory and test kits used for the
plasma testing must be notified in writing to Buyer at least 60 days prior to
the shipment of any plasma using such changed test kits. Documentation on the
test kits validation must be provided.

     GENERAL QA AND RA REQUIREMENTS

     -    Short Supply Agreement must be signed between each blood center
          (Exhibit D) and Buyer.

<PAGE>

                                       16

     -    Plasma Master File should be submitted once and then when versions are
          updated or new versions are issued.

     -    Supplier must receive written approval prior to shipment to Buyer
          after execution of the Short Supply Agreement.

     -    Description of the separation process after phlebotomy until storage.

     -    Traceability to the individual plasma units will be kept on file for
          not less than 15 years. This information will be made available to
          Buyer upon request.

     -    Buyer will have the right to inspect/audit relevant areas of the CBB
          facilities and the relevant documentation associated with the supply
          of plasma once a year. This rate may be adjusted whenever considered
          necessary.

     -    Look back procedures according to the current FDA guidelines is
          established and followed and Buyer's QA will be notified of any Look
          back action as required in the regulations.

     -    All preventive measures are taken to reduce the possible risk of
          transmission of Creutzfeldt - Jacob disease (CJD) and variant
          Creutzfeldt - Jacob disease (vCJD) in blood and blood products.

     -    All preventive measures are taken to reduce the possible risk of West
          Nile virus transmission and SARS in blood.

     -    Implementation of additional viral marker tests in the future if
          required by FDA authorities.

     -    Supplier will give Buyer the required regulatory support for
          submission to regulatory authorities for so long as this Agreement is
          in effect.

     -    Supplier will provide Buyer with the regulatory support services set
          forth hereto

               a)   In the event Buyer notifies Supplier of a recall, product
                    withdrawal, or field correction of any aspect of Buyer's
                    product, whether or not effected voluntarily or requested or
                    ordered by any federal or state agency or government agency,
                    Supplier shall fully cooperate with Buyer as necessary to
                    support any investigation such as recall, withdrawal or
                    correction.

               b)   In the event Supplier believes that a recall, product
                    withdrawal, or field correction is necessary or otherwise
                    appropriate, Supplier shall promptly notify and consult with
                    Buyer, and Supplier shall cooperate as reasonably necessary
                    to effectuate any such recall, withdrawal or correction.

               c)   Provision of regulatory documentation or letter of access to
                    approved files to support Buyer in obtaining new
                    authorizations, such as Marketing Authorizations or Clinical
                    Trial Authorizations for Buyer's product worldwide.

               d)   Preparation of Short Supply Agreement

<PAGE>

                                       17

               e)   Response to questions from regulatory authorities worldwide
                    in relation to Marketing Authorization Applications or
                    requests for Clinical Trial Authorizations for Buyer's
                    product worldwide.

               f)   Provision of regulatory information to support
                    variations/supplements to existing Marketing Authorizations
                    for Buyer's product upon reasonable request from Buyer,
                    fully cooperate with and provide all assistance requested by
                    Buyer to obtain and maintain all regulatory approvals that
                    are required to manufacture, distribute, use or sell Buyer's
                    product. Supplier shall also assist Buyer in responding to
                    requests and inquiries from applicable regulatory
                    authorities prior to, during and after regulatory review
                    periods, including without limitation, providing all data,
                    records and reports requested by Buyer relevant to such
                    review periods.

The documentation should state the quality of plasma; i.e. Frozen Recovered
Plasma for Fractionation (within 24h) or Recovered Plasma for Fractionation
(within 72h).

Required Documentation for approval of the donor center/blood bank:

Plasma Master File for each donor center/blood bank which should include at
least the following information:

     -    Establishment License

     -    Epidemiological data

     -    Donor Exclusion Criteria

     -    Laboratory System Information

     -    Maintain SOPs: (Buyer can review and audit)

               -    Donor Record System

               -    Look back procedure

               -    Test Results Management

     -    Certificate of Quality (See Shipment Cover Sheet: Annex 1 to this
          Exhibit B)

     -    Bleeding List

Additional information might be requested by the Israeli Ministry of Health

Each time the Plasma Master File is being updated a copy is to be provided to
Buyer.

Documentation provided:

A list of the names, address, and license number and/or Establishment
Registration Number of all CBBs included in the shipment, and the period of
collection for the plasma in the shipment, indicating the earliest and latest
donation date.

<PAGE>

                                       18

1.   A complete bleeding list indicating the name and address of the donor
     center, identification number of donation to be found on the plasma unit,
     collection date, confirmation of negative test results for each test
     required above, and donation volume.

     A signed and approved Certificate of Quality which includes the following
     information:

          a.   Customer name

          b.   Plasma Type

          c.   Shipment date

          d.   Delivery Number

          e.   Volume

          f.   Number of Bleeds

          g.   Number of Cases

          h.   Tests/Test Kit Name/Manufacturer/License/Results (viral markers
               and NAT-PCR) and certify that specifications were met.

          i.   Statements required:

                    Plasma was collected and separated according to supplier
                    approval procedures.

                    Plasma quality is that required for production of plasma
                    derivative products intended for human use in USA.

                    Plasma has been collected in FDA licensed facilities under
                    CGMP guidelines and in accordance with the code of Federal
                    regulations CFR 21. Bleeding lists will be signed by the QA
                    responsible person

                    Plasma was collected and separated according to Supplier
                    approval procedures.

                    Statement regarding freezing and storage conditions

2.   Documentation indicating information such as name of the product, the
     quantity in liters, and the number of containers in the shipment, and other
     standard requirements.

3.   Documentation to be provided with the shipment

          a.   Certificate of Quality

          b.   A copy of the bleeding lists in each carton for the individual
               units of plasma contained in that carton and a detailed
               description of the CBB from where the plasma has been collected
               from the approved list of CBBs as appears in Exhibit A.

4.   Electronic file: In addition, Blood Centers will establish an electronic
     file packing list similar to the Exhibit D (shipped 5-50-2003.csv) within 6
     days after contract signature

QUALITY CONTROL BY CUSTOMER:

Units are removed and rejected if:

<PAGE>

                                       19

          -    They cannot be identified or have improper documentation.

          -    They have no date or incorrect date.

          -    They are pink or red colored or exhibit signs of hemolysis or
               signs of excessive lipemia (based on visual test).

          -    They are broken.

          -    The unit does not appear in the bleeding list (surplus
               bag/container).

          -    They are under filled (<100ml).

          -    There is Lookback information on a particular unit.

          -    The unit is positive for a viral marker/NAT test.

          -    The label content of the unit is not correspondent to the data
               reported on the shipping list.

          -    Anti-D Reclassification plasma.

If significant in quantity, these rejected units will be deducted from future
invoices of the supplier.

<PAGE>

                                       20

                              ANNEX 1 TO EXHIBIT B

                   SHIPMENT COVER SHEET AND LETTER OF TESTING
                    CERTIFICATION FOR RECOVERED PLASMA FROZEN
            (FROZEN WITHIN 24HOURS) SHIPPED AT -20 degrees OR COLDER.

Blood Center Name: _____________________________________________________________

Address: _______________________________________________________________________

City, State, Zip: ______________________________________________________________

F.D.A. License #: ______________________________________________________________

Telephone: _____________________________________________________________________

Fax: ___________________________________________________________________________

TO: OMRIX BIOPHARMACEUTICALS LTD.
    Tel-Hashomer POB 888
    Kiryat-Ono 55000, Israel

Date of shipment: ______________________________________________________________

Bill of Lading #: __________________________ Reference Number: _________________

Number of Cartons: ____________ (Carton numbers: From ____________ to _________)

The shipment contains _______________ plasma units,and liters of plasma.

All donations are from bleed date ________ to bleed date ________

<TABLE>
<CAPTION>
                                                                  FDA
Screening Test     Test Kit Name   Generation   Manufacturer   License #
--------------     -------------   ----------   ------------   ---------
<S>                <C>             <C>          <C>            <C>
HBsAg
anti-HIV 1 and 2
anti-HCV
HCV by NAT
HIV by NAT
Anti-Syphilis
</TABLE>

<PAGE>

                                       21

<TABLE>
<S>                <C>             <C>          <C>            <C>
HTLV I/II
</TABLE>

Plasma bag (type, manufacturer): _______________________________________________
Anticoagulant: _________________________________________________________________

It is certified that all units in this shipment are tested and found
non-reactive for HIV-1 RNA, HCV RNA, HBsAg, HTLV I/II and for antibodies to HIV
1/2 and HCV with FDA licensed tests above. In addition, all units have tested
negative in the serological test for syphilis (STS) listed above.

Signature of Responsible Person
                                ------------------------------------------------
Date
     ----------------------

<PAGE>

                                       22

                   SHIPMENT COVER SHEET AND LETTER OF TESTING
                    CERTIFICATION FOR RECOVERED PLASMA FROZEN
            (FROZEN WITHIN 72 HOURS) SHIPPED AT -20 degrees OR COLDER.

Blood Center Name: _____________________________________________________________

Address: _______________________________________________________________________

City, State, Zip: ______________________________________________________________

F.D.A. License #: ______________________________________________________________

Telephone: _____________________________________________________________________

Fax: ___________________________________________________________________________

TO: OMRIX BIOPHARMACEUTICALS LTD.
    Tel-Hashomer POB 888
    Kiryat-Ono 55000, Israel

Date of shipment: ______________________________________________________________

Bill of Lading #: ____________________ Reference Number: _______________________

Number of Cartons: ___________ (Carton numbers: From ___________ to ___________)

The shipment contains _________ plasma units, and liters of plasma.

All donations are from bleed date _____________ to bleed date _____________

<TABLE>
<CAPTION>
                                                                  FDA
Screening Test     Test Kit Name   Generation   Manufacturer   License #
--------------     -------------   ----------   ------------   ---------
<S>                <C>             <C>          <C>            <C>
HBsAg
anti-HIV 1 and 2
anti-HCV
HCV by NAT
HIV by NAT
Anti-Syphilis
HTLV I/II
</TABLE>

<PAGE>

                                       23

Plasma bag (type, manufacturer): _______________________________________________

Anticoagulant: _________________________________________________________________

It is certified that all units in this shipment are tested and found
non-reactive for HIV-1 RNA, HCV RNA, HBsAg, HTLV I/II and for antibodies to HIV
1/2 and HCV with FDA licensed tests above. In addition, all units have tested
negative in the serological test for syphilis (STS) listed above.

Signature of Responsible Person
                                ------------------------------------------------
Date
     ------------------------

<PAGE>

                                       24

EXHIBIT C - SHORT SUPPLY AGREEMENT

                             SHORT SUPPLY AGREEMENT

As a supplier of Recovered Human Plasma to OMRIX BIOPHARMACEUTICALS, LTD.,
hereinafter "OMRIX", for use in the manufacture of licensed plasma products for
injection, the undersigned agrees to:

     1.   Comply with all applicable laws, rules, regulations, and guidelines,
          including those of the U.S. Food and Drug Administration, which are
          referenced in the Short Supply provisions of 21 CFR 601.22 and latest
          version of OMRIX Recovered Plasma Specifications and Requirements.

     2.   Permit inspection of your facility, procedures, and records by OMRIX
          personnel, the Food and Drug Administration, and other applicable
          regulatory bodies.

     3.   Establish procedures, inspections, tests, or other arrangements
          necessary to assure full compliance with all applicable regulations,
          including continued physical control and accountability of Recovered
          Human Plasma until shipment to OMRIX. Upon request, furnish OMRIX with
          a copy of such procedures, inspections, tests, or other arrangements,
          and advise OMRIX of any changes which could affect the continued
          safety, purity, and potency of the Recovered Human plasma collected
          for OMRIX.

     4.   This Short Supply Agreement covers all blood bank locations which are
          represented by the undersigned and have the same FDA License number.

NAME OF
ESTABLISHMENT:      ____________________________________________________________

ADDRESS:            ____________________________________________________________

CITY, STATE, ZIP:   ____________________________________________________________

FDA LICENSE NUMBER: ____________________________________________________________

AGREED TO BY:
                    ------------------------------------------------------------
                                  (Signature, Authorized Official)

                    ------------------------------------------------------------
                                     (Printed name and position)
DATE:
                    ------------------------------------------------------------

<PAGE>

                                       25

FOR OMRIX BIOPHARMACEUTICALS, LTD.:

AGREED TO BY:
              ------------------------------------------------------------
                            (Signature, Authorized Official)

              ------------------------------------------------------------
              (Printed name and position)
DATE:
              ---------------------------

<PAGE>

                                       26

EXHIBIT D - ELECTRONIC FILE

          Northwest Florida Inc.
          Blood Center
          2201 N. 9th Avenue Pensacola FL 32503
          Shipping Date: 5/5/2003
          Product Type: Frozen Recovered Plasma
          Number of Records: 720
          Quantity in Liters: 186.509

(Start Data)

<TABLE>
<CAPTION>
BOXNUMBER   UNITNUM   COLLECTED   VOLUME
---------   -------   ---------   ------
<S>         <C>       <C>         <C>
   3890     4340694   4/18/2003     0.24
   3890     4340697   4/18/2003     0.26
   3890     4340705   4/19/2003    0.282
   3890     4340708   4/19/2003    0.209
   3890     4507247   4/18/2003     0.27
   3890     4507258   4/18/2003    0.245
   3890     4562487   4/17/2003     0.22
   3890     4562488   4/17/2003    0.287
   3890     4619921   4/18/2003    0.301
   3890     4661220   4/18/2003    0.237
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]